

549,075

10/540075

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
15 July 2004 (15.07.2004)

PCT

(10) International Publication Number
WO 2004/058739 A1

(51) International Patent Classification⁷: **C07D 333/20, 333/28, 333/32, 333/64, 307/82, A61K 31/381, 31/343, A61P 25/00**

DK-2000 Frederiksberg (DK). WENZEL, TORNØE, Christian [DK/DK]; Sverrigsgade 20, 2. th., DK-2300 København S (DK).

(21) International Application Number:
PCT/DK2003/000906

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
18 December 2003 (18.12.2003)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
**PA200202012 27 December 2002 (27.12.2002) DK
60/436,697 27 December 2002 (27.12.2002) US**

(71) Applicant (*for all designated States except US*): **H. LUNDBECK A/S [DK/DK]; Otiliavej 9, DK-2500 Valby-Copenhagen (DK).**

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ROTTLÄNDER, Mario [DE/DK]; Svanemosen 10, DK-2670 Greve (DK). RITZEN, Andreas [SE/DK]; Hyltebjerg Alle 48B, 3. tv., DK-2720 Vanløse (DK). BANG, NØRGAARD, Morten [DK/DK]; Buddingevej 130A, DK-2800 Lyngby (DK). KHANZHIN, Nikolay [RU/DK]; Finsensvej 44A, 4. tv.,**

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/058739 A1

(54) Title: **1,2,4-TRIAMINOBENZENE DERIVATIVES USEFUL FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM**

(57) Abstract: The present invention concerns 1,2,4-triaminobenzene derivatives of the general formula I or pharmaceutically acceptable salts thereof and the use thereof.

1,2,4-triaminobenzene derivatives, useful for treating disorders of the central nervous system.

Field of the invention

The present invention relates to novel 1,2,4-triaminobenzene derivatives being
5 openers of the KCNQ family potassium channels. The compounds are useful for the prevention, treatment and/or inhibition of disorders of the central nervous system.

Background of the invention

Ion channels are cellular proteins that regulate the flow of ions, including potassium, calcium, chloride and sodium into and out of cells. Such channels are present in all 10 animal and human cells and affect a variety of processes including neuronal transmission, muscle contraction and cellular secretion.

Humans have over 70 potassium channel subunits (Jentsch *Nature Reviews Neuroscience* 2000, 1, 21-30) with a great diversity with regard to both structure and function. Neuronal potassium channels, which are found in the brain, are primarily responsible for maintaining a negative resting membrane potential, as well as controlling membrane repolarisation following an action potential.

20 One subset of potassium channel genes is the KCNQ family. Mutations in four out of five KCNQ genes have been shown to underlie diseases including cardiac arrhythmias, deafness and epilepsy (Jentsch *Nature Reviews Neuroscience* 2000, 1, 21-30).

25 The KCNQ4 gene is thought to encode the molecular correlate of potassium channels found in outer hair cells of the cochlea and in Type I hair cells of the vestibular apparatus, mutations in which lead to a form of inherited deafness.

30 KCNQ1 (KvLQT1) is co-assembled with the product of the KCNE1 (minimal K(+) channel protein) gene in the heart to form a cardiac-delayed rectifier-like K(+) current. Mutations in this channel can cause one form of inherited long QT syndrome type 1 (LQT1), as well as being associated with a form of deafness (Robbins *Pharmacol Ther* 2001, 90, 1-19).

The genes KCNQ2 and KCNQ3 were discovered in 1988 and appear to be mutated in an inherited form of epilepsy known as benign familial neonatal convulsions (Rogawski *Trends in Neurosciences* 2000, 23, 393-398). The proteins encoded by the KCNQ2 and KCNQ3 genes are localised in the pyramidal neurons of the human cortex and hippocampus, regions of the brain associated with seizure generation and propagation (Cooper et al. *Proceedings National Academy of Science U S A* 2000, 97, 4914-4919).

KCNQ2 and KCNQ3 are two potassium channel subunits that form "M-currents" when expressed in vitro. The M-current is a non-inactivating potassium current found in many neuronal cell types. In each cell type, it is dominant in controlling membrane excitability by being the only sustained current in the range of action potential initiation (Marroon *Annual Review Physiology* 1997, 59, 483-504). Modulation of the M-current has dramatic effects on neuronal excitability, for example, activation of the current will reduce neuronal excitability. Thus, openers of these KCNQ channels will reduce excessive neuronal activity in conditions such as seizures and diseases characterised by excessive neuronal activity such as epilepsy and neuropathic pain.

Retigabine (D-23129; N-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester) and analogues thereof are disclosed in EP554543. Retigabine is an anti-convulsive compound with a broad spectrum and potent anticonvulsant properties, both in vitro and in vivo. It is active after oral and intraperitoneal administration in rats and mice in a range of anticonvulsant tests including: electrically induced seizures, seizures induced chemically by pentylenetetrazole, picrotoxin and N-methyl-D-aspartate (NMDA) and in a genetic animal model, the DBA/2 mouse (Rostock et al. *Epilepsy Research* 1996, 23, 211-223). In addition, retigabine is active in the amygdala kindling model of complex partial seizures, further indicating that this compound has potential for anti-convulsive therapy. In clinical trials, retigabine has recently shown effectiveness in reducing the incidence of seizures in epileptic patients (Bialer et al. *Epilepsy Research* 2002, 51, 31-71).

Retigabine has been shown to activate a K(+) current in neuronal cells and the pharmacology of this induced current displays concordance with the published pharmacology of the M-channel, which recently was correlated to the KCNQ2/3 K(+) pharmacology.

channel heteromultimer. This suggests that activation of KCNQ2/3 channels may be responsible for some of the anticonvulsant activity of this agent (Wickenden et al. *Molecular Pharmacology* 2000, 58, 591-600) – and that other agents working by the same mechanism may have similar uses.

5

KCNQ 2 and 3 channels have been reported to be upregulated in models of neuropathic pain (Wickenden et al. *Society for Neuroscience Abstracts* 2002, 454.7), and potassium channel modulators have been hypothesised to be active in both neuropathic pain and epilepsy (Schroder et al. *Neuropharmacology* 2001, 40, 888-10 898; Blackburn-Munro and Jensen *European Journal of Pharmacology* 2003, 460, 109-116). Furthermore, the localisation of KCNQ channel mRNA is reported in brain and other central nervous system areas associated with pain (Goldstein et al. *Society for Neuroscience Abstracts* 2003, 53.8).

15

In addition to a role in neuropathic pain, the expression of mRNA for KCNQ 2-5 in the trigeminal and dorsal root ganglia and in the trigeminal nucleus caudalis implies that openers of these channels may also affect the sensory processing of migraine pain (Goldstein et al. *Society for Neuroscience Abstracts* 2003, 53.8).

20

Recent reports demonstrate that mRNA for KCNQ 3 and 5, in addition to that for KCNQ2, are expressed in astrocytes and glial cells. Thus KCNQ 2, 3 and 5 channels may help modulate synaptic activity in the CNS and contribute to the neuroprotective effects of KCNQ channel openers (Noda et al., *Society for Neuroscience Abstracts* 2003, 53.9). Retigabine and other KCNQ modulators may thus exhibit protection against the neurodegenerative aspects of epilepsy, as retigabine has been shown to prevent limbic neurodegeneration and the expression of markers of apoptosis following kainic acid-induced status epilepticus in the rat (Ebert et al. *Epilepsia* 2002, 43 Suppl 5, 86-95). This may have relevance for preventing the progression of epilepsy in patients, i.e. be anti-epileptogenic. Retigabine has also been shown to delay the progression of hippocampal kindling in the rat, a further model of epilepsy development (Tober et al. *European Journal Of Pharmacology* 1996, 303, 163-169).

Given that anticonvulsant compounds such as benzodiazepines and chlormethiazole are used clinically in the treatment of the ethanol withdrawal syndrome and that other

anticonvulsant compounds e.g. gabapentin, are very effective in animal models of this syndrome (Watson et al. *Neuropharmacology* 1997, 36, 1369-1375), we expect that other anticonvulsant compounds such as KCNQ openers will also be effective in this condition.

5

mRNA for KCNQ 2 and 3 subunits are found in brain regions associated with anxiety and emotional behaviours such as bipolar disorder e.g. hippocampus and amygdala (Saganich et al. *Journal of Neuroscience* 2001, 21, 4609-4624), and retigabine is reportedly active in some animal models of anxiety-like behaviour (Hartz et al. 10 *Journal of Psychopharmacology* 2003, 17 suppl 3, A28,B16), and other clinically used anticonvulsant compounds are used in the treatment of bipolar disorder.

WO 200196540 discloses the use of modulators of the M-current formed by expression of KCNQ2 and KCNQ3 genes for insomnia, whilst WO 2001092526 15 discloses that modulators of KCNQ5 can be utilized for the treatment of sleep disorders.

WO01/022953 describes the use of retigabine for prophylaxis and treatment of 20 neuropathic pain such as allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine.

WO02/049628 describes the use of retigabine for the prevention, treatment, inhibition and amelioration of anxiety disorders such as anxiety, generalized anxiety disorder, 25 panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia and specific phobias.

30 WO97/15300 describes the use of retigabine for the treatment of neurodegenerative disorders such as Alzheimer's disease, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced encephalopathy and other infection-related encephalopathies being caused by rubella viruses, herpes viruses, borrelia and by unknown pathogens, Creutzfeld-Jakob disease, Parkinson's disease, trauma-

induced neurodegenerations, and neuronal hyperexcitation states such as in medicament withdrawal or by intoxication, neurodegenerative disorders of the peripheral nervous system such as polyneuropathies and polyneuritides.

5 Hence, there is a great desire for novel compounds, which are potent openers of the KCNQ family potassium channels.


Also desired are novel compounds with improved properties relative to known compounds, which are openers of the KCNQ family potassium channels, such as 10 retigabine. Improvement of one or more of the following parameters is desired: half-life, clearance, selectivity, interactions with other medications, bioavailability, potency, formulability, chemical stability, metabolic stability, membrane permeability, solubility and therapeutic index. The improvement of such parameters may lead to improvements such as:

- 15
- an improved dosing regime by reducing the number of required doses a day,
 - ease of administration to patients on multiple medications
 - reduced side effects,
 - enlarged therapeutic index,
 - improved tolerability and/or
 - 20 • improved compliance.

Summary of the invention

Accordingly, one object of the present invention is to provide novel compounds, 25 which are potent openers of the KCNQ family potassium channels.

The compounds of the invention are 1,2,4-triaminobenzene derivatives of the general formula I or pharmaceutically acceptable salts thereof



wherein


R¹, R², R^{2'}, R³, X, Z, Y and **q** are as defined below.

5

The invention further relates to a pharmaceutical composition comprising a compound of formula I, and the use thereof.

10 Description of the invention

The present invention relates to novel 1,2,4-triaminobenzene derivatives of formula I



15 wherein

R¹ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl;

20

R² and **R^{2'}** are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, aryl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl-C₁₋₆-alk(en/yn)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl;

R^3 is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, aryl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, aryl- C_{1-6} -alk(en/yn)yl, hydroxy- C_{1-6} -alk(en/yn)yl, aryl- C_{3-8} -cycloalk(en)yl, $NR^{10}R^{10'}$ - C_{1-6} -alk(en/yn)yl,
5 $NR^{10}R^{10'}$ - C_{3-8} -cycloalk(en)yl and hydroxy- C_{3-8} -cycloalk(en)yl; wherein
 R^{10} and $R^{10'}$ are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, hydroxy- C_{1-6} -alk(en/yn)yl, hydroxy- C_{3-8} -cycloalk(en)yl, hydroxy- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{3-8} -cycloalk(en)yl, halo- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, cyano- C_{3-8} -cycloalk(en)yl and cyano- C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, or
10 R^{10} and $R^{10'}$ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms;

15

X is CO or SO_2 ;



Z is O or NR^4 , wherein

R^4 is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, hydroxy- C_{1-6} -alk(en/yn)yl and hydroxy- C_{3-8} -cycloalk(en)yl; or
20 R^3 and R^4 together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms, the ring formed by R^3 and R^4 and the nitrogen atom is optionally substituted with one or more substituents independently selected from C_{1-6} -alk(en/yn)yl, aryl and aryl- C_{1-6} -alk(en/yn)yl;
25

q is 0 or 1;

30 and

Y represents a heteroaryl of formula II or III



wherein

5 W is O or S;

m is 0,1, 2 or 3;

n is 0, 1, 2, 3 or 4;

10

p is 0 or 1; and

each R⁵ is independently selected from the group consisting of C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, aryl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl-C₁₋₆-alk(en/yn)yl,
15 acyl, halogen, halo-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, -CO-NR⁶R^{6'}, cyano, nitro, -NR⁷R^{7'}, -S-R⁸, -SO₂R⁸ and SO₂OR⁸;

wherein

20 R⁶ and R^{6'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl and aryl;

25 R⁷ and R^{7'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl and acyl;
and

R⁸ is selected from the group consisting of C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl and -NR⁹R^{9'}; wherein

R⁹ and R^{9'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl;

or pharmaceutically acceptable salts thereof.

5

When q is 0 then R³ is attached to X, whereas when q is 1 then R³ is attached to Z, which is attached to X. X-(Z)_q-R³ may thus represent X-R³, X-O-R³ or X-NR³R⁴.

10

In a particular embodiment, the present invention relates to a compound of formula I, wherein

R¹, R², R^{2'}, X, and q are as defined above; and

R³ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-

15 cycloalk(en)yl, aryl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl; and

Z is as defined above with the proviso that R⁴ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl; and

20 Y is as defined above with the proviso that each R⁵ is independently selected from the group consisting of C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, aryl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl-C₁₋₆-alk(en/yn)yl, acyl, halogen, halo-C₁₋₆-alk(en/yn)yl, -CO-NR⁶R^{6'}, cyano, nitro, -NR⁷R^{7'}, -S-R⁸, -SO₂R⁸ and SO₂OR⁸;

or pharmaceutically acceptable acid addition salts thereof.

25

In one embodiment, R¹ is selected from the group consisting of acyl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl.

30 In another embodiment, the invention relates to such compounds wherein R¹ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl.

In one preferred embodiment, the invention relates to such compounds wherein \mathbf{R}^1 is selected from the group consisting of hydrogen and $\text{C}_{1-6}\text{-alk(en/yn)yl}$.

5 In a particular embodiment, the invention relates to such compounds wherein \mathbf{R}^1 is a hydrogen atom.

In another particular embodiment, the invention relates to such compounds wherein \mathbf{R}^1 is $\text{C}_{1-6}\text{-alk(en/yn)yl}$.

10

In one embodiment, at least one of \mathbf{R}^2 and $\mathbf{R}^{2'}$ is selected from the group consisting of aryl, aryl- $\text{C}_{1-6}\text{-alk(en/yn)yl}$, acyl, hydroxy- $\text{C}_{1-6}\text{-alk(en/yn)yl}$ and hydroxy- $\text{C}_{3-8}\text{-cycloalk(en)yl}$.

15 In another embodiment, at least one of \mathbf{R}^2 and $\mathbf{R}^{2'}$ is selected from the group consisting of hydrogen, $\text{C}_{1-6}\text{-alk(en/yn)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl}$ and $\text{C}_{3-8}\text{-cycloalk(en)yl-C}_{1-6}\text{-alk(en/yn)yl}$.

20 In yet another embodiment, the invention relates to such compounds wherein at least one of the substituents \mathbf{R}^2 and $\mathbf{R}^{2'}$ is a hydrogen atom.

In yet another embodiment, the invention relates to such compounds, wherein both \mathbf{R}^2 and $\mathbf{R}^{2'}$ are hydrogen atoms.

25

In one embodiment, \mathbf{R}^3 is selected from the group consisting of hydroxy- $\text{C}_{1-6}\text{-alk(en/yn)yl}$, aryl- $\text{C}_{3-8}\text{-cycloalk(en)yl}$, $\text{NR}^{10}\text{R}^{10'}\text{-C}_{1-6}\text{-alk(en/yn)yl}$, $\text{NR}^{10}\text{R}^{10'}\text{-C}_{3-8}\text{-cycloalk(en)yl}$ and hydroxy- $\text{C}_{3-8}\text{-cycloalk(en)yl}$; wherein \mathbf{R}^{10} and $\mathbf{R}^{10'}$ are independently selected from the group consisting of hydrogen, $\text{C}_{1-6}\text{-alk(en/yn)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl-C}_{1-6}\text{-alk(en/yn)yl}$, hydroxy- $\text{C}_{1-6}\text{-alk(en/yn)yl}$, hydroxy- $\text{C}_{3-8}\text{-cycloalk(en)yl}$, hydroxy- $\text{C}_{3-8}\text{-cycloalk(en)yl-C}_{1-6}\text{-alk(en/yn)yl}$, halo- $\text{C}_{1-6}\text{-alk(en/yn)yl}$, halo- $\text{C}_{3-8}\text{-cycloalk(en)yl}$, halo- $\text{C}_{3-8}\text{-cycloalk(en)yl-C}_{1-6}\text{-alk(en/yn)yl}$, cyano- $\text{C}_{1-6}\text{-alk(en/yn)yl}$, cyano- $\text{C}_{3-8}\text{-cycloalk(en)yl}$ and cyano- $\text{C}_{3-8}\text{-cycloalk(en)yl-C}_{1-6}\text{-alk(en/yn)yl}$; or

\mathbf{R}^{10} and $\mathbf{R}^{10'}$ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms.

- 5 In yet another embodiment, the invention relates to such compounds wherein \mathbf{q} is 1, \mathbf{Z} is NR^4 , and \mathbf{R}^3 is a hydrogen atom.

In yet another embodiment, the invention relates to such compounds wherein \mathbf{R}^3 is different from a hydrogen atom.

- 10 In yet another embodiment, \mathbf{R}^3 is selected from the group consisting of $\text{C}_{1-6}\text{-alk(en/yn)yl}$, $\text{C}_{3-8}\text{-cycloalk(en)yl}$, aryl, $\text{C}_{3-8}\text{-cycloalk(en)yl-C}_{1-6}\text{-alk(en/yn)yl}$ and aryl- $\text{C}_{1-6}\text{-alk(en/yn)yl}$.

- 15 In yet another embodiment, the invention relates to such compounds wherein \mathbf{R}^3 is selected from the group consisting of $\text{C}_{1-6}\text{-alk(en/yn)yl}$ and aryl- $\text{C}_{1-6}\text{-alk(en/yn)yl}$.

In yet another embodiment, the invention relates to such compounds wherein \mathbf{R}^3 is $\text{C}_{1-6}\text{-alk(en/yn)yl}$.

- 20 In yet another embodiment, \mathbf{R}^3 is $\text{C}_{3-8}\text{-cycloalk(en)yl-C}_{1-6}\text{-alk(en/yn)yl}$.

In yet another embodiment, the invention relates to such compounds wherein \mathbf{R}^3 is aryl- $\text{C}_{1-6}\text{-alk(en/yn)yl}$.

25

In one embodiment, the invention relates to such compounds wherein \mathbf{X} is SO_2 .

In yet another embodiment, the invention relates to such compounds wherein \mathbf{X} is CO .

30

In one embodiment, \mathbf{q} is 0.

In yet another embodiment, the invention relates to such compounds wherein X is CO and q is 0.

5 In yet another embodiment, the invention relates to such compounds wherein X is CO and q is 0 and R³ is different from aryl.

In another embodiment, q is 1.

10 In one embodiment, the invention relates to such compounds wherein q is 1 and Z is NR⁴.

15 In one embodiment, q is 1, Z is NR⁴, and R³ and R⁴ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms, the ring formed by R³ and R⁴ and the nitrogen atom is optionally substituted with one or more substituents independently selected from C₁₋₆-alk(en/yn)yl, aryl and aryl-C₁₋₆-alk(en/yn)yl.

20 In another embodiment, q is 1, Z is NR⁴ and R⁴ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl.

In yet another embodiment, q is 1, Z is NR⁴ and R⁴ is a hydrogen atom.

25 In one embodiment, q is 1, Z is NR⁴, and at least one of R³ and R⁴ is different from a hydrogen atom.

In yet another embodiment, the invention relates to such compounds wherein q is 1 and Z is an oxygen atom.

30 In yet another embodiment, the invention relates to such compounds wherein X is CO, q is 1 and Z is an oxygen atom.

In yet another embodiment, the invention relates to such compounds wherein R² and R^{2'} are hydrogen atoms, X is CO, q is 1 and Z is an oxygen atom.

In yet another embodiment, the invention relates to such compounds wherein **W** is an oxygen atom.

5 In yet another embodiment, the invention relates to such compounds wherein **W** is a sulfur atom.

In yet another embodiment, the invention relates to such compounds wherein **W** is a sulphur atom and **X** is CO.

10 In yet another embodiment, the invention relates to such compounds wherein **W** is a sulphur atom and **q** is 0.

In yet another embodiment, the invention relates to such compounds wherein **W** is a sulphur atom, **X** is CO and **q** is 0.

15 In yet another embodiment, the invention relates to such compounds wherein **W** is a sulphur atom, **q** is 1 and **Z** is an oxygen atom.

20 In yet another embodiment, the invention relates to such compounds wherein **W** is a sulphur atom, **X** is CO, **q** is 1 and **Z** is an oxygen atom.

In yet another embodiment, **m** is 0.

25 In yet another embodiment, **m** is 1.

In yet another embodiment, **m** is 2.

30 In one embodiment, **m** is 3.

In yet another embodiment, **n** is 0.

In yet another embodiment, **n** is 1.

In one embodiment, **n** is 2, 3 or 4;

5

In one embodiment, **p** is 0.

In another embodiment, **p** is 1.

10

In one embodiment, at least one **R**⁵ is selected from the group consisting of acyl, -CO-NR⁶R⁶', nitro, -S-R⁸ and SO₂OR⁸.

15

In another embodiment, each **R**⁵ is independently selected from the group consisting of C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, aryl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl-C₁₋₆-alk(en/yn)yl, halogen, halo-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, cyano, -NR⁷R⁷' and -SO₂R⁸.

20

In yet another embodiment, each **R**⁵ is independently selected from the group consisting of C₁₋₆-alk(en/yn)yl, aryl, halogen, C₁₋₆-alk(en/yn)yloxy, -NR⁷R⁷' and -SO₂R⁸.

25

In yet another embodiment, the invention relates to such compounds wherein each **R**⁵ is independently selected from the group consisting of C₁₋₆-alk(en/yn)yl, halogen and -SO₂R⁸ wherein **R**⁸ is aryl.

In yet another embodiment, at least one substituent **R**⁵ is C₁₋₆-alk(en/yn)yl.

In yet another embodiment, at least one substituent **R**⁵ is aryl.

30

In yet another embodiment, at least one substituent **R**⁵ is C₁₋₆-alk(en/yn)yloxy.

In yet another embodiment, at least one substituent **R**⁵ is -SO₂R⁸.

In yet another embodiment, at least one substituent \mathbf{R}^5 is a halogen atom.

In yet another embodiment, at least one substituent \mathbf{R}^5 is a halogen atom, which is selected from the group consisting of chloro, bromo and iodo.

5

In yet another embodiment, at least one substituent \mathbf{R}^5 is fluoro.

In yet another embodiment, at least one substituent \mathbf{R}^5 is chloro.

10 In yet another embodiment, at least one substituent \mathbf{R}^5 is bromo.

In yet another embodiment, at least one substituent \mathbf{R}^5 is $-\text{NR}^7\text{R}^7'$.

15 In one embodiment, at least one substituent \mathbf{R}^5 is $-\text{NR}^7\text{R}^7'$; and at least one of \mathbf{R}^7 and \mathbf{R}^7' is aryl or acyl.

In one embodiment, at least one substituent \mathbf{R}^5 is $-\text{NR}^7\text{R}^7'$; and at least one of \mathbf{R}^7 and \mathbf{R}^7' is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl.

20

In another embodiment, at least one substituent \mathbf{R}^5 is $-\text{NR}^7\text{R}^7'$; and at least one of \mathbf{R}^7 and \mathbf{R}^7' is selected from the group consisting of hydrogen and C₁₋₆-alk(en/yn)yl.

25 In yet another embodiment, at least one substituent \mathbf{R}^5 is $-\text{NR}^7\text{R}^7'$; and at least one of \mathbf{R}^7 and \mathbf{R}^7' is C₁₋₆-alk(en/yn)yl.

In yet another embodiment, at least one substituent \mathbf{R}^5 is $-\text{NR}^7\text{R}^7'$; and both \mathbf{R}^7 and \mathbf{R}^7' are C₁₋₆-alk(en/yn)yl.

30 In one embodiment, at least one substituent \mathbf{R}^5 is $-\text{SO}_2\mathbf{R}^8$; and \mathbf{R}^8 is $-\text{NR}^9\text{R}^9'$; wherein \mathbf{R}^9 and \mathbf{R}^9' are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl.


In one embodiment, at least one substituent \mathbf{R}^5 is $-\text{SO}_2\mathbf{R}^8$; and \mathbf{R}^8 is selected from the group consisting of C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl and aryl.

5 In yet another embodiment, at least one substituent \mathbf{R}^5 is $-\text{SO}_2\mathbf{R}^8$; and \mathbf{R}^8 is aryl.


In yet another embodiment, the invention relates to such compounds wherein \mathbf{Y} is of
10 formula II.

In yet another embodiment, the invention relates to such compounds wherein \mathbf{Y} is of
formula III.

15 In yet another embodiment, the invention relates to such compounds wherein \mathbf{Y} is of
formula IIb or IIIb



IIb



IIIb

wherein \mathbf{W} , \mathbf{m} , \mathbf{n} , \mathbf{p} and \mathbf{R}^5 are as defined above.

20 In yet another embodiment, the invention relates to such compounds wherein \mathbf{Y} is of
formula IIb.

25 In yet another embodiment, the invention relates to such compounds wherein \mathbf{m} is 0
and \mathbf{Y} is of formula IIb.

In yet another embodiment, the invention relates to such compounds wherein \mathbf{Y} is of
formula IIIb.

In yet another embodiment, the invention relates to such compounds wherein n is 0 and Y is of formula IIIb.





5 In yet another embodiment, the invention relates to such compounds wherein p is 0 and Y is of formula IIIb.

In yet another embodiment, the invention relates to such compounds wherein n is 0, p is 0 and Y is of formula IIIb.

10 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIb and $n + p$ is 1, in a particular aspect thereof n is 1 and p is 0 and in another particular aspect thereof n is 0 and p is 1.

15 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIb and $n + p$ is 2, in a particular aspect thereof n is 2 and p is 0; and in another particular aspect thereof n is 1 and p is 1.

20 In yet another embodiment, the invention relates to such compounds wherein Y is of the below formula IIb¹, IIb², IIb³, IIIb¹, IIIb², IIIb³ or IIIb⁴:



wherein

W is as defined above;

5 **r** is 0, 1 or 2;

s is 0, 1, 2 or 3; and

R^{5'} and **R**^{5''} are independently defined as **R**⁵ and each **R**⁵ is independently as defined above.

10 In yet another embodiment, the invention relates to such compounds wherein:

- m is 0 and Y is of formula IIb; or
 - n is 0 and Y is of formula IIIb; or
 - p is 0 and Y is of formula IIIb; or
 - n is 0, p is 0 and Y is of formula IIIb; or
- 5 • Y is of formula IIIb and $n + p$ is 1, in a particular aspect thereof n is 1 and p is 0 and in another particular aspect thereof n is 0 and p is 1; or
- Y is of formula IIIb and $n + p$ is 2, in a particular aspect thereof n is 2 and p is 0; and in another particular aspect thereof n is 1 and p is 1; or
 - Y is of the formula IIb¹; or IIb²; or IIb³; or IIIb¹; or IIIb²; or IIIb³; or IIIb⁴.

10

In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIb¹; or IIb²; or IIb³; or wherein m is 0 and Y is of formula IIb.

15 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIb¹.

In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIb².

20 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIb³.

In yet another embodiment, the invention relates to such compounds wherein

- Y is of formula IIIb¹; or IIIb²; or IIIb³; or IIIb⁴; or
- 25 • n is 0 and Y is of formula IIIb; or
- p is 0 and Y is of formula IIIb; or
- n is 0, p is 0 and Y is of formula IIIb; or
- Y is of formula IIIb and $n + p$ is 1, in a particular aspect thereof n is 1 and p is 0 and in another particular aspect thereof n is 0 and p is 1; or
- 30 • Y is of formula IIIb and $n + p$ is 2, in a particular aspect thereof n is 2 and p is 0 and in another particular aspect thereof n is 1 and p is 1.



In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIb¹.

5 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIb².

In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIb³.

10 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIb⁴.

15 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIc or IIIc



IIc

IIIc

wherein W, m, n, p and R⁵ are as defined above.

20 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIc.

In yet another embodiment, the invention relates to such compounds wherein m is 0 and Y is of formula IIc.

25 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIc.

In yet another embodiment, the invention relates to such compounds wherein n is 0 and Y is of formula IIIc.

In yet another embodiment, the invention relates to such compounds wherein p is 0








5 and Y is of formula IIIc.

In yet another embodiment, the invention relates to such compounds wherein n is 0, p is 0 and Y is of formula IIIc.

10 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIc and $n + p$ is 1, in a particular aspect thereof n is 1 and p is 0 and in another particular aspect thereof n is 0 and p is 1.

15 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIc and $n + p$ is 2, in a particular aspect thereof n is 2 and p is 0 and in another particular aspect thereof n is 1 and p is 1.

20 In yet another embodiment, the invention relates to such compounds wherein Y is of the below formula IIc¹, IIc², IIc³, IIIc¹, IIIc², IIIc³ or IIIc⁴:



wherein

W is as defined above;

5 **r** is 0, 1 or 2;

s is 0, 1, 2 or 3; and

R^{5'} and **R**^{5''} are independently defined as **R**⁵ and each **R**⁵ is independently as defined above.

10 In yet another embodiment, the invention relates to such compounds wherein:

- m is 0 and Y is of formula IIc; or
 - n is 0 and Y is of formula IIIc; or
 - p is 0 and Y is of formula IIIc; or
 - n is 0, p is 0 and Y is of formula IIIc; or
- 5 • Y is of formula IIIc and $n + p$ is 1, in a particular aspect thereof n is 1 and p is 0 and in another particular aspect thereof n is 0 and p is 1; or
- Y is of formula IIIc and $n + p$ is 2, in a particular aspect thereof n is 2 and p is 0 and in another particular aspect thereof n is 1 and p is 1; or
 - Y is of the formula IIc¹; or IIc²; or IIc³; or IIIc¹; or IIIc²; or IIIc³; or IIIc⁴.

10

In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIc¹; or IIc²; or IIc³; or m is 0 and Y is of formula IIc.

15

In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIc¹.

In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIc².

20

In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIc³.

In yet another embodiment, the invention relates to such compounds wherein

- Y is of formula IIIc¹; or IIIc²; or IIIc³; or IIIc⁴; or
- 25 • n is 0 and Y is of formula IIIc; or
- p is 0 and Y is of formula IIIc; or
- n is 0, p is 0 and Y is of formula IIIc; or
- Y is of formula IIIc and $n + p$ is 1, in a particular aspect thereof n is 1 and p is 0 and in another particular aspect thereof n is 0 and p is 1; or
- 30 • Y is of formula IIIc and $n + p$ is 2, in a particular aspect thereof n is 2 and p is 0 and in another particular aspect thereof n is 1 and p is 1.

In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIc¹.

5 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIc².

In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIc³.

10 In yet another embodiment, the invention relates to such compounds wherein Y is of formula IIIc⁴.

In yet another embodiment, the invention relates to such compounds wherein r is 0.

15 In yet another embodiment, the invention relates to such compounds wherein r is 1.

In yet another embodiment, the invention relates to such compounds wherein r is 2.

20

In yet another embodiment, the invention relates to such compounds wherein s is 0

25 In yet another embodiment, the invention relates to such compounds wherein s is 1, 2 or 3.

In yet another embodiment, the invention relates to such compounds wherein Y of formula II represents

- 30
- IIb¹; or IIb²; or IIb³; or IIc¹; or IIc²; or IIc³; or
 - a group of formula IIb wherein m is 0; or
 - a group of formula IIc wherein m is 0.

In yet another embodiment, the invention relates to such compounds wherein \mathbf{Y} of formula II represents

- IIb^1 ; or IIb^2 ; or IIb^3 ; or
- a group of formula IIb wherein \mathbf{m} is 0; or
- 5 • a group of formula IIc wherein \mathbf{m} is 0.

In yet another embodiment, the invention relates to such compounds wherein \mathbf{Y} of formula III represents

- IIIb^1 ; or IIIb^2 ; or IIIb^3 ; or IIIb^4 ; or IIIc^1 ; or IIIc^2 ; or IIIc^3 ; or IIIc^4 ; or
- 10 • a group of formula IIIb wherein \mathbf{n} is 0; or
- a group of formula IIIb wherein \mathbf{p} is 0; or
- a group of formula IIIb wherein \mathbf{n} is 0 and \mathbf{p} is 0; or
- a group of formula IIIb wherein $\mathbf{n} + \mathbf{p}$ is 1, in a particular aspect thereof \mathbf{n} is 1 and \mathbf{p} is 0 and in another particular aspect thereof \mathbf{n} is 0 and \mathbf{p} is 1; or
- 15 • \mathbf{Y} is of formula IIIb and $\mathbf{n} + \mathbf{p}$ is 2, in a particular aspect thereof \mathbf{n} is 2 and \mathbf{p} is 0 and in another particular aspect thereof \mathbf{n} is 1 and \mathbf{p} is 1;
- a group of formula IIIc wherein \mathbf{n} is 0; or
- a group of formula IIIc wherein \mathbf{p} is 0; or
- 20 • a group of formula IIIc wherein \mathbf{n} is 0 and \mathbf{p} is 0; or
- a group of formula IIIc wherein $\mathbf{n} + \mathbf{p}$ is 1, in a particular aspect thereof \mathbf{n} is 1 and \mathbf{p} is 0 and in another particular aspect thereof \mathbf{n} is 0 and \mathbf{p} is 1; or
- \mathbf{Y} is of formula IIIc and $\mathbf{n} + \mathbf{p}$ is 2, in a particular aspect thereof \mathbf{n} is 2 and \mathbf{p} is 0 and in another particular aspect thereof \mathbf{n} is 1 and \mathbf{p} is 1.

25

In yet another embodiment, the invention relates to such compounds wherein \mathbf{Y} of formula III represents

- IIIb^2 ; or IIIc^2 ; or
- a group of formula IIIb wherein \mathbf{n} is 0 and \mathbf{p} is 0; or
- 30 • a group of formula IIIc wherein \mathbf{n} is 0 and \mathbf{p} is 0.

In yet another embodiment, the invention relates to such compounds wherein \mathbf{m} is 0 and \mathbf{Y} is of formula II, in particular aspects thereof \mathbf{Y} is of formula IIb or IIc .

In yet another embodiment m is 1, and Y is of formula II, in a particular aspect thereof Y is of formula IIb, and in more particular aspects thereof Y is of formula IIb¹, IIb² or IIb³.

5 In yet another embodiment m is 1, R^5 is selected from the group consisting of C₁₋₆-alk(en/yn)yl and halogen, and Y is of formula II, in a particular aspect thereof Y is of formula IIb, and in more particular aspects thereof Y is of formula IIb¹, IIb² or IIb³.

10 In yet another embodiment, the invention relates to such compounds wherein m is 1, R^5 is C₁₋₆-alk(en/yn)yl and Y is of formula II, in a particular aspect thereof Y is of formula IIb, and in more particular aspects thereof Y is of formula IIb¹ or IIb³.

15 In yet another embodiment, the invention relates to such compounds wherein m is 1, R^5 is a halogen atom such as bromo or chloro or fluoro, and Y is of formula II, in a particular aspect thereof Y is of formula IIb, and in more particular aspects thereof Y is of formula IIb¹, IIb² or IIb³.

20 In yet another embodiment, the invention relates to such compounds wherein m is 1, R^5 is bromo or chloro, and Y is of formula II, in a particular aspect thereof Y is of formula IIb, and in more particular aspects thereof Y is of formula IIb¹, IIb² or IIb³.

25 In yet another embodiment, the invention relates to such compounds wherein m is 1, R^3 is C₁₋₆-alk(en/yn)yl, and Y is of formula II, in a particular aspect thereof Y is of formula IIb, and in more particular aspects thereof Y is of formula IIb¹, IIb² or IIb³, and in a most particular aspect thereof Y is of formula IIb³.

30 In yet another embodiment, the invention relates to such compounds wherein R^1 is C₁₋₆-alk(en/yn)yl, m is 1, R^5 is C₁₋₆-alk(en/yn)yl or halogen and Y is of formula II, in a particular aspect thereof Y is of formula IIb, and in a more particular aspect thereof Y is of formula IIb³.

In yet another embodiment, the invention relates to such compounds wherein n is 0, p is 0 and Y is of formula III; in particular aspects thereof Y is of formula IIIb or IIIc.

In yet another embodiment, the invention relates to such compounds wherein n is 1 and Y is of formula III, in particular aspects thereof Y is of formula IIIb or IIIc, and in more particular aspects thereof Y is of formula III b^2 , III b^3 or III c^2 .

- 5 In yet another embodiment, the invention relates to such compounds wherein $n + p$ is 1 and Y is of formula III; in a particular aspect thereof Y is of formula IIIc; and in a more particular aspect thereof Y is of formula III c^2 .

- 10 In yet another embodiment, the invention relates to such compounds wherein $n + p$ is 2 and Y is of formula III; in a particular aspect thereof Y is of formula IIIb; and in a more particular aspect thereof Y is of formula III b^2 or III b^3 .

In yet another embodiment, Y is not of formula II when W is an oxygen atom.

- 15 In yet another embodiment, the compound of formula I contains no more than 3 aryl groups as defined herein.

- 20 The compounds of the following list and pharmaceutically acceptable salts thereof are preferred:

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

- 25 {2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

- 30 {2-Amino-4-[(6-chloro-3-methoxy-benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

- {2-Amino-4-[(4-bromo-3-methoxy-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(5-phenyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- 5 {2-Amino-4-[(3-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- (2-Amino-4-{[4-(4-chloro-benzenesulfonyl)-3-methyl-thiophen-2-ylmethyl]-amino}-phenyl)-carbamic acid ethyl ester;
- {2-Amino-4-[(3-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- 10 {2-Amino-4-[(5-fluoro-benzofuran-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(4-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- 15 {2-Amino-4-[(5-ethyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-ethyl-amino]-phenyl}-carbamic acid ethyl ester;
- 20 {2-Amino-4-[(benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(5-dimethyl-amino-benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(5-dimethyl-amino-3-methyl-benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- 25 {2-Amino-4-[(5-fluoro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester;
- 30 {2-Amino-4-[(benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester;
- N-{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)amino]-phenyl}-2-(4-fluoro-phenyl)-acetamide; and

N-{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)amino]-phenyl}-3,3-dimethylbutyramide.

In a particular aspect, the compounds of the following list and pharmaceutically

5 acceptable acid addition salts thereof are preferred:

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

10 {2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

15 {2-Amino-4-[(6-chloro-3-methoxy-benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

20 {2-Amino-4-[(4-bromo-3-methoxy-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-phenyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

25 {2-Amino-4-[(3-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

(2-Amino-4-[(4-(4-chloro-benzenesulfonyl)-3-methyl-thiophen-2-ylmethyl)-amino]-phenyl)-carbamic acid ethyl ester;

{2-Amino-4-[(3-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

30 {2-Amino-4-[(5-fluoro-benzofuran-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(4-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-ethyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
{2-Amino-4-[(thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester; and
{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-ethyl-amino]-phenyl}-carbamic acid
5 ethyl ester.

In one aspect, the invention provides a pharmaceutical composition comprising at least one compound of formula I as defined above or a pharmaceutically acceptable salt thereof in a therapeutically effective amount together with one or more
10 pharmaceutically acceptable carriers or diluents.

In one particular aspect, the invention provides a pharmaceutical composition comprising at least one compound of formula I as defined above or a pharmaceutically acceptable acid addition salt thereof in a therapeutically effective
15 amount together with one or more pharmaceutically acceptable carriers or diluents.

The invention provides a pharmaceutical composition for oral or parenteral administration, said pharmaceutical composition comprising at least one compound of formula I or a salt thereof in a therapeutically effective amount together with one or
20 more pharmaceutically acceptable carriers or diluents.

In one embodiment, the compounds of the invention may be administered as the only therapeutically effective compound.

25 In another embodiment, the compounds of the invention may be administered as a part of a combination therapy, i.e. the compounds of the invention may be administered in combination with other therapeutically effective compounds having e.g. anti-convulsive properties. The effects of such other compounds having anti-convulsive properties may include, but not be limited to, activities on:
30 • ion channels such as sodium, potassium or calcium channels
• the excitatory amino acid systems e.g. blockade or modulation of NMDA receptors

- the inhibitory neurotransmitter systems e.g. enhancement of GABA release or blockade of GABA-uptake and/or
- membrane stabilisation effects.

5 Current anti-convulsive medications include, but are not limited to, tiagabine, carbamazepine, sodium valproate, lamotrigine, gabapentin, pregabalin, ethosuximide, levetiracetam, phenytoin, topiramate, zonisamide as well as members of the benzodiazepine and barbiturate class.

10 The compounds of the invention are considered useful for increasing ion flow in a voltage-dependent potassium channel.

The compounds of the invention are considered useful for preventing, treating and/or inhibiting a disorder or condition being responsive to an increased ion flow in a potassium channel such as the KCNQ family potassium ion channels.

15 In one aspect, the compounds of the invention have been found to have effect on potassium channels of the KCNQ family, in particular on the KCNQ2 subunit.

20 According to one aspect, the compounds of the invention are considered to be useful for preventing, treating and/or inhibiting a variety of disorders of the central nervous system such as seizure disorders such as convulsions, epilepsy and status epilepticus; anxiety disorders such as anxiety, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, 25 separation anxiety disorder, agoraphobia and specific phobias.

Accordingly, the compounds of the invention are considered to be useful for preventing, treating and/or inhibiting a variety of disorders of the central nervous system such as:

30 • **seizure disorders** such as convulsions, epilepsy and status epilepticus;

- **neuropathic pain** such as allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine;

- anxiety disorders such as anxiety, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia, specific phobias;
- 5 • neurodegenerative disorders such as Alzheimer's disease, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced encephalopathy and other infection-related encephalopathies being caused by rubella viruses, herpes viruses, borrelia and by unknown pathogens, Creutzfeld-Jakob disease, Parkinson's disease, trauma-induced neurodegenerations, and
- 10 • neuronal hyperexcitation states such as in medicament withdrawal or by intoxication, neurodegenerative disorders of the peripheral nervous system such as polyneuropathies and polyneuritides.

Accordingly, the compounds of the invention are considered useful for preventing,
15 treating and/or inhibiting disorders or conditions such as seizure disorders, neuropathic and migraine pain disorders, anxiety disorders and neurodegenerative disorders.

According to one particular aspect, the compounds of the invention are considered to
20 be useful for preventing, treating and/or inhibiting seizure disorders such as convulsions, epilepsy and status epilepticus.

According to another particular aspect, the compounds of the invention are considered useful for preventing, treating and/or inhibiting neuropathic and migraine pain
25 disorders such as allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine.

The compounds of the invention are further considered useful for preventing, treating and/or inhibiting anxiety disorders such as anxiety, generalized anxiety disorder,
30 panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia, anxiety disorder

due to general medical condition and substance-induced anxiety disorder and specific phobias.

The compounds of the invention are further considered useful for preventing, treating
5 and/or inhibiting neurodegenerative disorders such as Alzheimer's disease,
Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced
encephalopathy and other infection-related encephalopathies being caused by rubella
viruses, herpes viruses, borrelia and by unknown pathogens, Creutzfeld-Jakob disease,
Parkinson's disease, trauma-induced neurodegenerations, and neuronal
10 hyperexcitation states such as in medicament withdrawal or by intoxication.

In another aspect, the invention provides compounds showing effect in one or more of the following tests:

- 15 • “Relative efflux through the KCNQ2 channel”
 Which is a measure of the potency of the compound at the target channel
- “Maximum electroshock”
 Which is a measure of seizures induced by non-specific CNS stimulation by
 electrical means
- 20 • “Pilocarpine induced seizures”
 Seizures induced by pilocarpine are often difficult to treat with many existing
 antiseizure medications and so reflect a model of “drug resistant seizures”
- “Electrical seizure-threshold tests” and “Chemical seizure-threshold tests”
 These models measure the threshold at which seizures are initiated, thus being
25 models that detect whether compounds could delay seizure initiation.
- “Amygdala kindling”
 Which is used as a measure of disease progression, as in normal animals the
 seizures in this model get more severe as the animal receives further
 stimulations.

According to one particular aspect of the invention, the compounds are KCNQ2 active with an EC₅₀ of less than 15000nM as measured by the test "Relative efflux through the KCNQ2 channel" which is described below.

5 According to one particular aspect of the invention, the compounds are KCNQ2 active with an EC₅₀ of less than 1500nM as measured by the test "Relative efflux through the KCNQ2 channel" which is described below.

10 According to another particular aspect of the invention, the compounds are KCNQ2 active with an EC₅₀ of less than 150nM as measured by the test "Relative efflux through the KCNQ2 channel" which is described below.

According to another particular aspect of the invention, the compounds have an ED₅₀ of less than 15 mg/kg in the test "Maximum electroshock" which is described below.

15 According to yet another particular aspect of the invention, the compounds have an ED₅₀ of less than 5 mg/kg in the test "Maximum electroshock" which is described below.

20 According to one particular aspect of the invention, the compounds have an ED₅₀ of less than 5 mg/kg in the "Electrical seizure -threshold test" and/or "Chemical seizure - threshold test" which is described below.

25 Some compounds have few or clinically insignificant side effects. Some of the compounds are thus tested in models of the unwanted sedative, hypothermic and ataxic actions of the compounds.

30 Some compounds have an appropriate half-life and an appropriate clearance meaning that patients only have to take their tablets e.g. once or twice daily. This is easy for the patient to remember and so aids compliance with the drug therapy.

Some of the compounds have a large therapeutic index between anticonvulsant efficacy and side-effects such as impairment of locomotor activity or ataxic effects as

measured by performance on a rotating rod. This means that the compounds will expectedly be well tolerated in patients permitting high doses to be used before side-effects are seen. Thereby compliance with the therapy will expectedly be good and administration of high doses may be permitted making the treatment more efficacious
5 in patients who would otherwise have side effects with other medications.

Definitions

The term heteroatom refers to a nitrogen, oxygen or sulphur atom.

10

Halogen means fluoro, chloro, bromo or iodo.

The expression C₁₋₆-alk(en/yn)yl means a C₁₋₆-alkyl, C₂₋₆-alkenyl or a C₂₋₆-alkynyl group.

15

The term C₁₋₆-alkyl refers to a branched or unbranched alkyl group having from one to six carbon atoms inclusive, including but not limited to methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-2-dimethyl-1-propyl and 2-methyl-1-propyl.

20

Similarly, C₂₋₆-alkenyl and C₂₋₆-alkynyl, respectively, designate such groups having from two to six carbon atoms, including one double bond and one triple bond respectively, including but not limited to ethenyl, propenyl, butenyl, ethynyl, propynyl and butynyl.

25

The expression C₃₋₈-cycloalk(en)yl means a C₃₋₈-cycloalkyl- or cycloalkenyl group.

The term C₃₋₈-cycloalkyl designates a monocyclic or bicyclic carbocycle having three to eight C-atoms, including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl, etc.

30

The term C₃₋₈-cycloalkenyl designates a monocyclic or bicyclic carbocycle having three to eight C-atoms and including one double bond.

When two substituents together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms, then a monocyclic ring system is formed by 4 to 8 atoms selected from the nitrogen atom, 1-7 carbonatoms and 0-3 heteroatoms selected from N, S or

5 O. Examples of such ring systems are azetidine, beta-lactame, pyrrolidine, piperidine, piperazine, morpholine, pyrrole, oxazolidine, thiazolidine, imidazolidine, tetrazole and pyrazole.

The term aryl refers to aromatic systems such as pyridine, thiazole, oxazole, phenyl, naphthyl, thiophene and furan, which are optionally substituted with one or more substituents independently being hydroxy, halogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, C₁₋₆-alkoxy, C₃₋₈-alkoxy, acyl, nitro or cyano, -CO-NH-C₁₋₆-alk(en/yn)yl, -CO-N(C₁₋₆-alk(en/yn)yl)₂, -NH-C₁₋₆-alk(en/yn)yl, -N(C₁₋₆-alk(en/yn)yl)₂, -S- C₁₋₆-alk(en/yn)yl, 15 -SO₂-C₁₋₆-alk(en/yn)yl, -SO₂O-C₁₋₆-alk(en/yn)yl, -NH₂, -SO₂N(C₁₋₆-alk(en/yn)yl)₂ or -SO₂NH-C₁₋₆-alk(en/yn)yl; or two adjacent substituents may together with the aromatic group to which they are attached form a 4-8 membered ring, which optionally contains one or two heteroatoms.

20 When two adjacent substituents together with the aromatic group to which they are attached form a 4-8 membered ring, which optionally contains one or two heteroatoms, then a ring system is formed by 4-8 atoms selected from 3-8 carbonatoms and 0-2 heteroatoms selected from N, S, or O. Such two adjacent substituents may together form:

-(CH₂)_n--CH₂-, -CH=CH-(CH₂)_m--, -CH₂-CH=CH-(CH₂)_p--, -CH=CH-CH=CH-, -(CH₂)_n--O-, -O-(CH₂)_m--O-, -CH₂-O-(CH₂)_p--O-, -CH₂-O-CH₂-O-CH₂-, -(CH₂)_n--S-, -S-(CH₂)_m--S-, -CH₂-S-(CH₂)_p--S-, -CH₂-S-CH₂-S-CH₂-, -(CH₂)_n--NH-, -NH-(CH₂)_m--NH-, -CH₂-NH-(CH₂)_p--NH-, -CH=CH-NH-, 30 -O-(CH₂)_m--NH-, -CH₂-O-(CH₂)_p--NH- or -O-(CH₂)_p--NH-CH₂-, -S-(CH₂)_m--NH-, -N=CH-NH-, -N=CH-O- or -N=CH-S-, wherein m'' is 1, 2 or 3, n'' is 2, 3 or 4 and p'' is 1 or 2.

As used herein, the term acyl refers to formyl, C₁₋₆-alk(en/yn)ylcarbonyl, C₃₋₈-cycloalk(en)ylcarbonyl, arylcarbonyl, aryl-C₁₋₆-alk(en/yn)ylcarbonyl or a C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl-carbonyl group, wherein C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and aryl are as defined above.

5

The term halo-C₁₋₆-alk(en/yn)yl designates C₁₋₆-alk(en/yn)yl being substituted with one or more halogen atoms, including but not limited to trifluormethyl. Similarly, halo-C₃₋₈-cycloalk(en)yl designates C₃₋₈-cycloalk(en)yl being substituted with one or more halogen atoms and halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, designates C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl being substituted with one or more halogen atoms.

10

In the term C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and C₁₋₆-alk(en/yn)yl are as defined above.

15

Furthermore, terms such as hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, aryl-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₃₋₈-cycloalk(en)yloxy, C₁₋₆-alk(en/yn)ylcarbonyl, C₃₋₈-cycloalk(en)ylcarbonyl, arylcarbonyl, aryl-C₁₋₆-alk(en/yn)ylcarbonyl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)ylcarbonyl, aryl-C₃₋₈-cycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl-C₃₋₈-cycloalk(en)yl, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl, cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, NR¹⁰R^{10'}-C₁₋₆-alk(en/yn)yl and NR¹⁰R^{10'}-C₃₋₈-cycloalk(en)yl etc. designate groups in which the C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and aryl are as defined above.

20

25

The salts of the invention are preferably pharmaceutically acceptable salts. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.

30

The pharmaceutically acceptable salts of the invention are preferably acid addition salts.

Acid addition salts include salts of inorganic acids as well as organic acids.

The acid addition salts of the invention are preferably pharmaceutically acceptable salts of the compounds of the invention formed with non-toxic acids.

Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, 5 succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanesulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline.

10

Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Such acid addition salts can be formed by methods known to the person skilled in the art. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in *J. Pharm. Sci.* 1977, 66, 2, which is incorporated herein by reference.

Also intended as pharmaceutically acceptable acid addition salts are the hydrates,

20 which the present compounds are able to form.

Furthermore, when a double bond or a fully or partially saturated ring system is present in the molecule, geometric isomers may be formed. It is intended that any 25 geometric isomers, as separated, pure or partially purified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules having a bond with restricted rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.

30 Furthermore, some of the compounds of the present invention may exist in different tautomeric forms and it is intended that any tautomeric forms that the compounds are able to form are included within the scope of the present invention.

Further, the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and

the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.

Some of the compounds of the present invention contain chiral centres and such 5 compounds exist in the form of isomers (i.e. enantiomers). The invention includes all such isomers and any mixtures thereof including racemic mixtures.

Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, 10 and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds of the present invention can also be resolved into their optical antipodes, e.g. by fractional 15 crystallization of d- or l- tartrates, mandelates or camphorsulphonate salts. The compounds of the present invention may also be resolved by the formation of diastereomeric derivatives.

Additional methods for the resolution of optical isomers, known to those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A. Collet and S. 20 Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).

Optically active compounds can also be prepared from optically active starting materials.

25

The invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming pharmacologically active substances. In general, such prodrugs will be functional 30 derivatives of the compounds of the general formula I, which are readily convertible in vivo into the required compound of the formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

The invention also encompasses active metabolites of the present compounds.

Whenever mentioned in relation to the compounds of the formulas I, the terms epilepsy and epilepsies embrace any of the epilepsies, epileptic syndromes and 5 epileptic seizures referred to in International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Commission on Classification and Terminology of the International League Against Epilepsy. *Epilepsia* 1981 22: 489-501 and in International League Against Epilepsy: Proposal for revised classification of epilepsies and epileptic syndromes. Commission 10 on Classification and Terminology of the International League Against Epilepsy. *Epilepsia* 1989 30(4): 389-399.

Pharmaceutical compositions

15 The compounds of this invention are generally utilized as the free base or as a pharmaceutically acceptable salt thereof. Representative examples are mentioned above.

If desired, the pharmaceutical composition of the invention may comprise the 20 compound of formula I in combination with further pharmacologically active substances such as those described in the foregoing.

The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including 25 buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.

30 The pharmaceutical compositions of this invention or those which are manufactured in accordance with this invention may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, granules, pellets, a troche dragees, pills or lozenges, solutions or suspensions in aqueous or non-aqueous liquids,

or oil-in-water or water-in-oil liquid emulsions, elixirs, syrups, etc., or parenterally in the form of solutions for injection. Other pharmaceutical compositions for parenteral administration include dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use.

- 5 Depot injectable formulations are also contemplated as being within the scope of the present invention. Other suitable administration forms include suppositories, sprays, ointments, creams, gels, inhalants, dermal patches, implants etc.

- 10 For preparing such compositions, methods well known in the art may be used, and any pharmaceutically acceptable carriers, diluents, excipients or other additives normally used in the art may be used.

- 15 Conveniently, the compounds of the invention are administered in unit dosage form containing said compounds in an amount of about 0.01 to 100 mg. The total daily dose is usually in the range of about 0.05 - 500 mg or even 0.05 - 1500 mg or 0.05 - 3000 mg, and most preferably about 0.1 to 50 mg of the active compound of the invention. For parenteral routes such as intravenous, intrathecal, intramuscular and similar administration, typically, doses are in the order of about half the dose employed for oral administration.

- 20 The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19 Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.

- 25 30 Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.

The pharmaceutical formulations of the invention may be prepared by conventional

methods in the art. Tablets may e.g. be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tabletting machine. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.

Where appropriate, a solid dosage form may be prepared with coatings such as enteric 10 coatings or they can be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art.

If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft 15 gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

For parenteral administration, solutions of the novel compounds of the invention in sterile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or 20 peanut oil may be employed. Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilising the solution and filling it in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, 25 antioxidants, etc. Accordingly, such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of liquid carriers are syrup, peanut oil, olive oil, phospho lipids, fatty acids, fatty acid amines, polyoxyethylene and water. Similarly, the carrier or diluent may include any sustained release material

known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.

5 Typical examples of recipes for the formulation of the invention are as follows:

- 1) Tablets containing 5.0 mg of a compound of the invention calculated as the free base:

	Compound of formula I	5.0 mg
10	Lactose	60 mg
	Maize starch	30 mg
	Hydroxypropylcellulose	2.4 mg
	Microcrystalline cellulose	19.2 mg
	Croscarmellose Sodium Type A	2.4 mg
15	Magnesium stearate	0.84 mg

- 2) Tablets containing 0.5 mg of a compound of the invention calculated as the free base:

	Compound of formula I	0.5 mg
20	Lactose	46.9 mg
	Maize starch	23.5 mg
	Povidone	1.8 mg
	Microcrystalline cellulose	14.4 mg
	Croscarmellose Sodium Type A	1.8 mg
25	Magnesium stearate	0.63 mg

- 3) Syrup containing per millilitre:

	Compound of formula I	25 mg
	Sorbitol	500 mg
30	Hydroxypropylcellulose	15 mg
	Glycerol	50 mg
	Methyl-paraben	1 mg
	Propyl-paraben	0.1 mg
	Ethanol	0.005 mL

Flavour	0.05 mg
Saccharin sodium	0.5 mg
Water	ad 1 mL

5 4) **Solution for injection containing per millilitre:**

Compound of formula I	0.5 mg
Sorbitol	5.1 mg
Acetic Acid	0.05 mg
Saccharin sodium	0.5 mg
Water	ad 1 mL

10


15

Preparation of the compounds of the invention

The compounds of the invention of the general formula I,

wherein R^1 , R^2 , $R^{2'}$, R^3 , X, Y, Z and q are as defined above

20 are prepared by the methods as represented in the scheme and as described below:



5



In the below, any of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^6' , R^7 , R^7' , R^8 , R^9 , R^9' , R^{10} , R^{10}' , X , Y , Z , W , m , n , p and q are as defined above.

- 5 Compounds of the general formula VII are prepared according to methods known to chemists skilled in the art (v. Bebenburg et al. *Chemiker Zeitung* 1979, Sonderdruck 103, 3-15) and as outlined below:

Compounds of the general formula IV are prepared by the reaction of 4-nitroaniline with suitable electrophilic reagents, such as, but not limited to, acid chlorides, acid bromides, acid iodides, sulfonyl chlorides, isocyanates, carbonic acid anhydrides, activated esters, and alkyl halo-formates with or without the addition of bases, such as trialkyl amines, potassium carbonate, or lithium-, sodium-, or potassium alcoholates, in a suitable solvent, such as ethyl acetate, dioxane, tetrahydrofuran, acetonitrile or diethyl ether, at a suitable temperature, such as room temperature or reflux temperature, achieved by conventional heating or under microwave irradiation, followed by the reduction of the nitro group with a suitable reducing agent, such as sodium dithionite, iron or zinc powder in aqueous hydrochloric acid or hydrogen gas in the presence of a suitable hydrogenation catalyst such as palladium on activated carbon in suitable solvents such as methanol or ethanol, at a suitable temperature.

Compounds of the general formula V are prepared by the reaction of compounds of the general formula IV with a reagent forming a protecting group on the aniline group, for example phthalic anhydride, in a suitable solvent, such as glacial acetic acid, at a suitable temperature.

Compounds of the general formula VI are prepared from compounds of the general formula V by nitration reactions known to the chemist skilled in the art, such as reaction with fuming nitric acid, in a suitable solvent, such as glacial acetic acid, at a suitable temperature.

Compounds of the general formula VII are prepared from compounds of the general formula VI by deprotection of the aniline function with hydrazine hydrate in a suitable solvent, such as 1,2-dioxane, at a suitable temperature.

Alternatively, compounds of the general formula VII can be prepared from 2-nitro-1,4-diaminobenzene in 3 steps as shown in the scheme and as described below. In the first step, the less hindered and the more reactive aniline nitrogen is protected with an appropriate protecting group PG [*Protective Groups in Organic Synthesis*, 3rd Edition

- 5 T. W. Greene, P. G. M. Wuts, Wiley Interscience 1999] such as *tert*-butyloxycarbonyl group (a Boc group) by the reaction with the appropriate reagent forming protective group such as di-*tert*-butyl dicarbonate in an appropriate solvent such as acetonitrile and at appropriate temperature furnishing compounds of the general formula XI.
- 10 The compounds of the general formula XII are obtained from compounds of the general formula XI by the reaction with suitable electrophilic reagents forming R³-(Z)_q-X group such as alkyl, aryl or heteroaryl chloroformates or carbamoyl chlorides, acid chlorides, acid bromides, acid iodides, sulfonyl chlorides, isocyanates, carbonic acid anhydrides, activated carbonic acids with activating reagents such as
- 15 carbodiimides or others as known to chemists skilled in the art, in suitable solvents, such as acetonitrile, tetrahydrofuran, 1,2-dichloroethane or methylene chloride at a suitable temperature, such as room temperature or reflux achieved by conventional heating or under microwave irradiation, with or without addition of bases, such as magnesium oxide, potassium carbonate, trialkylamines, pyridine or sodium
- 20 hydrogencarbonate as described above for compounds of the general formula IV.

- The protecting group is removed by the methods known to chemists skilled in the art. In particular, the Boc group can be cleaved by treatment with an appropriate acid, for example trifluoroacetic acid, in the absence or presence of solvent such as methylene 25 chloride or toluene at the appropriate temperature furnishing compounds of the general formula VII.

Preparation of compounds of the general formula VIII:

- 30 Compounds of the general formula VII are subjected to reductive alkylation reactions, known to the chemist skilled in the art, with aldehydes of the general formulae IIa or IIIa, wherein R⁵, W, m, n and p are as described above, using reducing agents, such as sodium borohydride or sodium cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, water, dioxane or mixtures thereof, with or

without addition of catalytic amounts of acid, such as acetic acid, at a suitable temperature, to form compounds of the general formula VIII, wherein R¹ is hydrogen.

Alternatively, compounds of the general structure VII can be reacted with aldehydes 5 of the general structures IIa or IIIa in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, dioxane, xylene, or mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic acid or acidic ion exchange resin, at a suitable temperature, to form imines, that can be isolated by crystallisation or by evaporation of the solvent. The imines can then be reduced using reducing agents, 10 such as sodium borohydride or sodium cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, water, dioxane or mixtures thereof, to compounds of the general formula VIII, wherein R¹ is hydrogen.

Optionally, for variation of R¹, the obtained compounds of the general formula VIII 15 can be subjected to an additional reductive alkylation procedure using suitable aldehydes and reducing agents, such as sodium borohydride or sodium cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, water, dioxane or mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic acid, at a suitable temperature as described above. This procedure 20 can also be carried out *in-situ* after the first reductive alkylation with aldehydes of the general structures IIa or IIIa.

Alternatively, for variation of R¹, the obtained compounds of the general formula VIII can be subjected to an acylation reaction using suitable electrophilic reagents, such as 25 acid chlorides, acid bromides, acid iodides, sulfonyl chlorides, and alkyl haloformates with the addition of bases, such as trialkyl amines, potassium carbonate, or lithium-, sodium-, or potassium alcoholates, in a suitable solvent, such as ethyl acetate, dioxane, tetrahydrofuran, or diethyl ether, at a suitable temperature, as described above.

30

Compounds of the general formula IX, are formed by reduction of compounds of the general formula VIII with a suitable reducing agent such as sodium dithionite, iron or zinc powder in aqueous hydrochloric acid or acetic acid in the absence or presence of organic solvents such as tetrahydrofuran or ethanol, or hydrogen gas in the presence of

a suitable hydrogenation catalyst such as palladium on activated carbon in suitable solvents such as methanol or ethanol or water/tetrahydrofuran mixture, at an suitable temperature. The resulting compounds are identical to compounds of the invention of the general formula I, wherein R^2 and $R^{2'}$ are hydrogen, and wherein R^1, R^3, X, Y, Z ,
5 and q are as defined above.

Compounds of the general formula I, wherein R^1 is not hydrogen, and where R^2 and optionally $R^{2'}$ are not hydrogen, are obtained by the reaction of compounds of the general formula IX, wherein R^1 is not hydrogen, by using the following methods:

10

Introduction of R^2 by a reductive alkylation procedure using suitable aldehydes and reducing agents, such as sodium borohydride or sodium cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran, water, dioxane or mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic
15 acid, at a suitable temperature, as described above.

Optional introduction of $R^{2'}$ by an additional reductive alkylation procedure using suitable aldehydes and reducing agents, such as sodium borohydride or sodium cyanoborohydride in a suitable solvent, such as methanol, ethanol, tetrahydrofuran,
20 water, dioxane or mixtures thereof, with or without addition of catalytic amounts of acid, such as acetic acid, at a suitable temperature, as described above.

Alternatively, $R^{2'}$ or R^2 is introduced by an acylation reaction using suitable electrophilic reagents, such as acid chlorides, acid bromides, acid iodides, sulfonyl
25 chlorides, and alkyl halo-formates with the addition of bases, such as trialkyl amines, potassium carbonate, or lithium-, sodium-, or potassium alcoholates, in a suitable solvent, such as ethyl acetate, dioxane, tetrahydrofuran, or diethyl ether, at a suitable temperature, as described above.

30 To obtain compounds of the general formula I, where R^1 is hydrogen, and where R^2 and optionally $R^{2'}$ is not hydrogen, a protecting group, such as *tert*-butyloxycarbonyl is introduced as R^1 before the reduction of the nitro group, by methods known to the chemist skilled in the art. This protecting group is cleaved after the introduction of R^2 and optionally $R^{2'}$ by known methods.

Compounds of the general formulae IIa and IIIa are prepared by standard methods known to chemists skilled in the art as outlined below:

Reduction of a carboxylic acid ester with an appropriate reducing agent, such as diisobutyl aluminium hydride, followed by oxidation of the resulting benzylic alcohol with a suitable oxidant, such as tetrapropylammonium perruthenate/N-methylmorpholin-N-oxide, pyridinium chlorochromate, dimethylsulfoxide/oxalylchloride. Alternatively, compounds of the general formulae IIa and IIIa can be prepared by formylation reactions with dichloromethyl methyl ether and titanium tetrachloride (Gross et al, *Org. Synth. Coll.*, 1973 Vol V, 365; Fanghaenel et al. *J. Prakt. Chem.* 1997, 339, 277). Alternatively, compounds of the general formulae II and IIIa can be prepared by methods known to chemists skilled in the art, such as deprotonation of a heteroaromatic compound with a strong base, such as alkyllithium, and subsequent reaction with N,N-dimethylformamide. Alternatively, compounds of the general formulae IIa and IIIa can be prepared by methods known to chemists skilled in the art, such as halogen metal exchange reaction of halogen substituted heteroaromatic compounds, such as bromides or iodides, by the reaction with a metalating reagent, such as alkyllithium or alkylmagnesium halide or dialkylmagnesium. Alternatively, compounds of the general formulae IIa and IIIa can be prepared by methods known to chemists skilled in the art, such as reaction of thiophenes and benzothiophenes with phosphoryl chloride in the presence of *N*-methyl-*N*-phenyl formamide (King et al. *J. Org. Chem.* 1949, 14, 638) or *N,N*-dimethylformamide (Vilsmeier formylation, Raimundo et al. *J. Org. Chem.* 2002, 67, 205).

25

Examples

Analytical LC-MS data were obtained on a PE Sciex API 150EX instrument equipped with IonSpray source and Shimadzu LC-8A/SLC-10A LC system. Column: 30 X 4.6 mm Waters Symmetry C18 column with 3.5 μ m particle size; Solventsystem: A = water/trifluoroacetic acid (100:0.05) and B = water/acetonitrile/trifluoroacetic acid (5:95:0.03); Method: Linear gradient elution with 90% A to 100% B in 4 minutes and with a flow rate of 2 mL/min. Purity was determined by integration of the UV (254 nm) and ELSD trace. The retention times (RT or t_R) are expressed in minutes.

Preparative LC-MS-purification was performed on the same instrument. Column: 50 X 20 mm YMC ODS-A with 5 μm particle size; Method: Linear gradient elution with 80% A to 100% B in 7 minutes and with a flow rate of 22.7 mL/min. Fraction collection was performed by split-flow MS detection.

5

¹H NMR spectra were recorded at 500.13 MHz on a Bruker Avance DRX500 instrument or at 250.13 MHz on a Bruker AC 250 instrument. Deuterated chloroform (99.8%D) or dimethyl sulfoxide (99.8%D) were used as solvents. TMS was used as internal reference standard. Chemical shift values are expressed in ppm-values. The following abbreviations are used for multiplicity of NMR signals: s = singlet, d = doublet, t = triplet, q = quartet, qui = quintet, h = heptet, dd = double doublet, ddd = double double doublet, dt = double triplet, dq = double quartet, tt = triplet of triplets, m = multiplet and b = broad singlet. In certain cases, coupling constants, J, are given. Melting points (M.p.) were recorded on a Büchi B-540 apparatus and are uncorrected.

10

Preparation of intermediates

(4-Amino-phenyl)-carbamic acid ethyl ester.

4-Nitro-aniline (100 g, 0.72 mol) is dissolved in ethyl acetate (800 mL) and diisopropylethylamine (89.6 mL, 0.936 mol) is added. Ethyl chloroformate (252 mL, 1.45 mol) dissolved in ethyl acetate (200 mL) is added and the solution is stirred for 18 h at ambient temperature. The mixture is washed with 2M HCl (300 mL) and brine (300 mL), dried (MgSO_4) and concentrated *in vacuo* to half of the original volume. To the resulting solution is added palladium on activated carbon (10 g, 5% Pd, 50% H_2O) and the mixture is hydrogenated on a Parr apparatus ($\text{pH}_2 = 3$ bar) at ambient temperature for 12 hours. The mixture is filtered through Celite and the solvent evaporated *in vacuo* to give 118 g (90%) of the title compound as crystalline product. LC/MS (*m/z*) 180.9 (MH^+); $t_{\text{R}} = 0.60$ min. ¹H NMR (CDCl_3): 1.27 (t, 3H); 3.42 (b, , 2H, NH_2); 4.19 (q, 2H); 6.52 (b, 1H NH); 6.64 (m, 2H); 7.14.(m, 2H).

15

The following compound was prepared in an analogous fashion:

(4-Amino-phenyl)-carbamic acid propyl ester.

Yield: 98%. ¹H NMR (CDCl_3): 0.96 (t, 3H); 1.68 (m, 2H); 3.51 (b, 2H); 4.09 (t, 2H); 6.46 (b, 1H); 6.63 (d, 2H); 7.14 (m, 2H).

20

(4-Phtalimido-phenyl)-carbamic acid ethyl ester.

(4-Amino-phenyl)-carbamic acid ethyl ester (118 g, 0.65 mol) is dissolved in glacial acetic acid (2.0 L) under nitrogen and the mixture is heated to 90 °C. Phthalic anhydride (102.0 g, 0.69 mol) is added portionwise over 30 minutes and the reaction 5 is kept at 90 °C for 2 hours. The mixture is allowed to cool to ambient temperature and the precipitated solid is filtered off. The solid is washed on the filter with water (2 L) followed by diethylether (3 L) and then dried *in vacuo*. Yield 127 g (62%) title compound as white crystalline compound. LC/MS (*m/z*) 311.3 (MH⁺); *t_R* = 2.57 min. ¹H NMR (DMSO-*d*₆): 1.26 (t, 3H); 4.15 (q, 2H); 7.34 (dd, 2H); 7.58 (dd, 2H); 7.90 10 (ddd, 2H); 7.95 (ddd, 2H); 9.80 (s, 1H, NH).

The following compound was prepared in an analogous fashion:

(4-Phtalimido-phenyl)-carbamic acid propyl ester.

15 Yield: 81%.

(2-Nitro-4-phtalimido-phenyl)-carbamic acid ethyl ester.

(4-Phtalimido-phenyl)-carbamic acid ethyl ester (99.0 g, 0.32 mol) is suspended in glacial acetic acid (1.5 L) and heated to 90 °C. Fuming nitric acid (17.2 mL, 0.41 mol) 20 is added dropwise over 30 minutes at 90-95 °C. The reaction mixture is then stirred at 100 °C for 1 hour and cooled to ambient temperature. Crystallised solids are filtered off and washed with glacial acetic acid (500 mL), water (1 L) and diethylether (1 L) on the filter, then dried *in vacuo* to furnish 101 g (90%) of the title compound as a yellow solid. LC/MS (*m/z*) 355.0 (MH⁺); *t_R* = 3.34 min. ¹H NMR (DMSO-*d*₆): 1.25 (t, 25 3H); 4.16 (q, 2H); 7.81 (m, 2H); 7.93 (ddd, 2H); 7.99 (ddd, 2H); 6.15 (dd, 1H); 9.99 (s, 1H, NH).

The following compound was prepared in an analogous fashion:

(2-Nitro-4-phtalimido-phenyl)-carbamic acid propyl ester.

30 Yield: 70%.

(4-Amino-2-nitro-phenyl)-carbamic acid ethyl ester.

1,2-Dimethoxyethane (1.0 L) is added to (2-nitro-4-phtalimido-phenyl)-carbamic acid 35 ethyl ester (101 g, 0.28 mol) and the mixture is heated under reflux. Hydrazine

monohydrate (19.6 g, 0.39 mol) is added dropwise over 10 minutes and the mixture is stirred at reflux for 1.5 hours. Upon cooling to ambient temperature the mixture is filtered and the solids are washed with dimethoxyethane (250 mL) on the filter. The filtrate is concentrated by means of evaporation and the red crystalline product is recrystallized from toluene (350 mL), precipitated product is filtered off and dried *in vacuo*. The mother liquor is concentrated to half the original volume and left standing for 16 hours. Precipitated material is filtered off and recrystallized as before. The recrystallized solids are combined to furnish a total of 57.6 g (90%) dark red title compound. LC/MS (*m/z*) 225.1 (MH^+); t_R = 2.08 min. ^1H NMR (CDCl_3): 1.33 (t, 3H); 3.77 (s, 2H, NH_2); 4.23 (q, 2H); 6.98 (dd, 1H); 7.45 (d, 1H); 8.28 (d, 1H); 9.39 (s, 1H, NH).

The following compound was prepared in an analogous fashion:

15 *(4-amino-2-nitro-phenyl)-carbamic acid propyl ester.*
Yield: 91%. ^1H NMR (CDCl_3): 0.98 (t, 3H); 1.71 (m, 2H); 3.78 (b, 2H); 4.13 (t, 2H); 6.98 (dd, 1H); 7.44 (d, 1H); 8.27 (d, 1H); 9.39 (s, 1H).

20 *(4-Amino-3-nitro-phenyl)-carbamic acid tert-butyl ester.*

To a refluxing solution of 2-nitro-1,4-diaminobenzene (10.135 g, 66.18 mmol) in tetrahydrofuran (100 mL) Boc_2O (di-*tert*-butyl dicarbonate, 32.6 g, 149 mmol) was added by portions during 2 hours. The obtained solution was poured into heptane (2 L), sonicated for 15 minutes, filtered and dried *in vacuo* to furnish 13.40 g of the title compound as a red solid. Yield 80%. LC/MS (*m/z*) 295.4 ($[\text{M}+\text{H}+\text{MeCN}]^+$); t_R = 2.54 (UV, ELSD) 96%, 100%. ^1H NMR (DMSO-d_6): 1.47 (s, 9H); 6.96 (d, 1H); 7.24 (s, 2H, NH_2), 7.41 (dd, 1H); 8.20 (s, 1H); 9.28 (s, 1H, NH).

[4-(4-Chloro-benzenesulfonyl)-3-methyl-thiophen-2-yl]-methanol.

30 A solution of 4-(4-Chloro-benzenesulfonyl)-3-methyl-thiophene-2-carboxylic acid methyl ester (992 mg, 3.00 mmol) in dry tetrahydrofuran (20 mL) and dry CH_2Cl_2 (10 mL) was cooled to 0 °C under N_2 , and DIBAL-H (9.0 mL, 9.0 mmol, 1 M solution in toluene) was added. After 3 hours, another portion of DIBAL-H (4.5 mL, 4.5 mmol) was added, and stirring was continued for another 2 hours. The reaction was quenched

by the addition of saturated Rochelle salt solution (30 mL), and the mixture was stirred for 1 hour at room temperature. The phases were separated, the aqueous phase was extracted with EtOAc (2 × 50 mL) and the pooled organic layers were dried over Na₂SO₄ and evaporated *in vacuo*. The product was purified by chromatography on 5 silica gel on a FlashMaster system using as eluent heptane/ethyl acetate (linear gradient elution from 1:0 to 6:4). Fractions containing the product were pooled and evaporated *in vacuo* to yield the desired compound (788 mg, 87%). LC-MS: (m/z) = 285.2 (M-H₂O+H⁺), calcd for C₁₂H₁₀ClO₂S₂: 284.9805, t_R = 2.45 min. ¹H NMR (CDCl₃): 1.84 (t, J = 5.7 Hz, 1 H), 2.20 (s, 3 H), 4.73 (d, J = 5.7 Hz, 2 H), 7.49 (d, J = 8.5 Hz, 2 H), 7.84 (d, J = 8.5 Hz, 2 H), 8.18 (s, 1 H).

The following compounds were prepared analogously:

(3-Chloro-thiophen-2-yl)-methanol.

15 Yield: 73%. ¹H NMR (CDCl₃): 1.92 (b, 1 H), 4.81 (s, 2 H), 6.91 (d, J = 5.2 Hz, 1 H), 7.25 (d, J = 5.2 Hz, 1 H).

(5-Dimethylamino-benzo[b]thiophen-3-yl)-methanol.

Yield: 63%. ¹H NMR (CDCl₃): 1.62 (b, 1 H), 3.01 (s, 6 H), 4.89 (s, 2 H), 6.96 (dd, 1 H), 7.11 (d, 1 H), 7.34 (s, 1 H), 7.68, (d, J = 9.0 Hz, 1 H).

(5-Dimethylamino-3-methyl-benzo[b]thiophen-2-yl)-methanol.

Yield: 56%. ¹H NMR (CDCl₃): 1.69 (t, J = 5.9 Hz, 1 H), 2.35 (s, 3 H), 3.00 (s, 6 H), 4.88 (d, 2 H), 6.90 (d, 1 H), 6.93 (dd, 1 H), 7.63, (d, 1 H).

25

(4-Bromo-3-methoxy-thiophen-2-yl)-methanol.

A suspension of 4-bromo-3-hydroxy-thiophene-2-carboxylic acid methyl ester (948 mg, 4.00 mmol), dimethyl sulphate (0.57 mL, 6.0 mmol), and K₂CO₃ (1.11 g, 8.0 mmol) in acetone (10 mL) was heated under reflux for 4 hours. After cooling to room 30 temperature, water (25 mL) was added. The mixture was extracted with EtOAc (2 × 25 mL), and the extracts were pooled, dried over Na₂SO₄, and evaporated *in vacuo*. The residue was dissolved in dry tetrahydrofuran (20 mL), the solution was cooled to 0 °C under N₂, and DIBAL-H (12 mL, 12 mmol, 1 M solution in toluene) was added.

After 2 hours, another portion of DIBAL-H (6 mL, 6 mmol) was added, and stirring was continued for another 2 hours. The reaction was quenched by the addition of saturated Rochelle salt solution (30 mL), and the mixture was stirred for 1 hour at room temperature. The phases were separated, the aqueous phase was extracted with EtOAc (2×50 mL) and the pooled organic layers were dried over Na₂SO₄ and evaporated *in vacuo*. The product was purified by chromatography on silica gel on a FlashMaster system using as eluent heptane/ethyl acetate (linear gradient elution from 1:0 to 2:1). Fractions containing the product were pooled and evaporated *in vacuo* to yield the desired compound (482 mg, 54%). ¹H NMR (CDCl₃): 1.86 (b, 1 H), 3.90 (s, 3 H), 4.77 (s, 2 H), 7.15 (s, 1 H).

The following compound was prepared analogously:

(6-Chloro-3-methoxy-benzo[b]thiophen-2-yl)-methanol.

Yield: 75%. ¹H NMR (CDCl₃): 1.92 (t, $J = 5.9$ Hz, 1 H), 3.99 (s, 3 H), 4.90 (d, $J = 5.7$ Hz, 2 H), 7.33 (dd, $J = 1.9, 8.5$ Hz, 1 H), 7.64 (d, $J = 8.5$ Hz, 1 H), 7.73 (d, $J = 1.9$ Hz, 1 H).

20 Preparation of heteroaryl aldehydes of the general formula IIa and IIIa

4-(4-Chloro-benzenesulfonyl)-3-methyl-thiophene-2-carbaldehyde.

To a suspension of [4-(4-chloro-benzenesulfonyl)-3-methyl-thiophen-2-yl]-methanol (786 mg, 2.60 mmol), 4-methylmorpholine N-oxide (0.46 g, 3.9 mmol), and powdered 4 Å molecular sieves (1.3 g, activated by brief heating *in vacuo*) in CH₂Cl₂ (7 mL) was added tetrapropylammonium perruthenate (46 mg, 0.13 mmol). The resulting mixture was stirred for 1 hour, after which it was filtered through a plug of silica (*ca.* 25 g) eluting with EtOAc. The eluate was evaporated *in vacuo* and the product was purified by chromatography on silica gel on a FlashMaster system using as eluent heptane/ethyl acetate (linear gradient elution from 1:0 to 1:1). Fractions containing the product were pooled and evaporated *in vacuo* to yield the title compound (644 mg, 82%). ¹H NMR (CDCl₃): 2.60 (s, 3 H), 7.53 (d, $J = 9.0$ Hz, 2 H), 7.87 (d, $J = 8.5$ Hz, 2 H), 8.53 (s, 1 H), 10.01 (s, 1 H).

The following aldehydes were prepared analogously:

3-Chloro-thiophene-2-carbaldehyde.

Yield: 94%. ^1H NMR (CDCl_3): 7.07 (d, $J = 5.2$ Hz, 1 H), 7.72 (d, $J = 0.5, 4.7$ Hz, 1 H), 10.07 (d, $J = 0.9$ Hz, 1 H).

5 *4-Bromo-3-methoxy-thiophene-2-carbaldehyde.*

Yield: 45%. ^1H NMR (CDCl_3): 4.18 (s, 3 H), 7.60 (d, $J = 1.4$ Hz, 1 H), 10.08 (d, $J = 1.4$ Hz, 1 H).

6-Chloro-3-methoxy-benzo[b]thiophene-2-carbaldehyde.

10 Yield: 86%. ^1H NMR (CDCl_3): 4.34 (s, 3 H), 7.36 (dd, $J = 1.7, 8.7$ Hz, 1 H), 7.75 (d, $J = 1.4$ Hz, 1 H), 7.82 (d, $J = 8.5$ Hz, 1 H), 10.36 (s, 1 H).

5-Dimethylamino-benzo[b]thiophene-3-carbaldehyde.

15 Yield: 72%. ^1H NMR (CDCl_3): 3.05 (s, 6 H), 7.00 (dd, $J = 2.4, 9.0$ Hz, 1 H), 7.68 (d, $J = 9.0$ Hz, 1 H), 7.99 (d, $J = 2.8$ Hz, 1 H), 8.24 (s, 1 H), 10.11 (s, 1 H).

5-Dimethylamino-3-methyl-benzo[b]thiophene-2-carbaldehyde.

Yield: 73%. ^1H NMR (CDCl_3): 2.74 (s, 3 H), 3.03 (s, 6 H), 7.00 (d, $J = 2.4$ Hz, 1 H), 7.12 (dd, $J = 2.4, 9.0$ Hz, 1 H), 7.69 (d, $J = 9.0$ Hz, 1 H), 10.30 (s, 1 H).

20

5-Fluoro-benzofuran-3-carbaldehyde.

At a constant temperature of -60 °C dimethylsulfoxide (3.27 g, 41.8 mmol) in dichloromethane (10 mL) was added to a solution of oxalylchloride (2.65 g, 20.9 mmol) in dichloromethane (30 mL) and the solution was stirred for 15 minutes. 1-(5-Fluorobenzofuran-3-yl)methanol (3.16 g, 19.0 mmol) dissolved in dichloromethane (60 mL) was added dropwise at -60 °C. The mixture was stirred for 20 minutes followed by addition of triethylamine (9.61 g, 0.095 mmol). After stirring for 10 minutes, the reaction mixture was allowed to heat to ambient temperature and stirred for additional 20 minutes. The organic fraction was washed successively with 50 mL portions of water, 1N aqueous HCl, saturated aqueous sodium bicarbonate and brine, then dried (MgSO_4) and concentrated *in vacuo* to furnish crude title compound in quantitative yield as a beige crystalline solid. ^1H NMR (CDCl_3): 7.13 (dt, 1H); 7.50 (dd, 1H); 7.86 (dd, 1H); 8.30 (s, 1H); 10.15 (s, 1H).

5-Fluoro-thiophene-2-carbaldehyde.

To a solution of thiophene (4.8 mL, 60 mmol) in dry Et₂O (200 mL) at 0 °C was added *n*-BuLi (70 mL, 66 mmol, 0.95 M in hexane) dropwise, and the solution was stirred for 1 hour at -5 - 0 °C. Then the temperature was adjusted to -70 °C, and a 5 solution of (PhSO₂)₂NF (28.4 g, 90 mmol) in dry tetrahydrofuran (200 mL) was added, while maintaining the temperature below -50 °C. The resultant mixture was then slowly allowed to warm to room temperature overnight, 2 N NaOH (300 mL) was added, the mixture was filtered, and the organic layer was washed with 2 N NaOH (2 x 300 mL) and saturated NH₄Cl (300 mL) and was then dried over Na₂SO₄.

10 Distillation using a 40 cm Vigreux column removed most of the Et₂O, and final co-distillation with heptane (50 mL) yielded a solution of 20.7 mmol 2-fluorothiophene and 4.6 mmol thiophene (determined by ¹H NMR using 200 μL of DME as internal standard) in ca. 100 mL of tetrahydrofuran and heptane (bp. 60 – 100 °C). This solution was cooled to 0 °C and *n*-BuLi (44 mL, 41 mmol, 0.95 M in hexane) was 15 added dropwise. After 1 hour, a solution of DMF (4.8 mL, 62 mmol) in Et₂O (15 mL) was added dropwise, and stirring was continued for another 1 hour at 0 °C. The reaction was then quenched with saturated NH₄Cl (200 mL) and extracted with Et₂O (2 x 200 mL), and the extract was dried over Na₂SO₄. Most of the solvent was removed by distillation at atmospheric pressure (40 cm Vigreux column) and the dark 20 residue was then vacuum distilled to yield a ca. 10:1 mixture of 5-fluoro-thiophene-2-carbaldehyde and thiophene-2-carbaldehyde (bp. 78-79 °C, 25 mmHg) as a golden oil (1.32 g, 44%). This mixture was used without further purification. ¹H NMR (CDCl₃): 6.65 (d, *J* = 4.2, 1 H), 7.50 (d, *J* = 3.8 Hz, 1 H), 9.76 (d, *J* = 4.2 Hz, 1 H).

25 **Preparation of intermediates of general formula VII**

Intermediates of the general formula VII were prepared by a general method as described below for the preparation of {4-[*(5*-Fluoro-benzofuran-3-ylmethyl)-amino]-2-nitro-phenyl}-carbamic acid ethyl ester, or by a general method as described below for the preparation of N-(4-Amino-2-nitrophenyl)-2-(4-fluorophenyl)acetamide.

30

{4-[*(5*-Fluoro-benzofuran-3-ylmethyl)-amino]-2-nitro-phenyl}-carbamic acid ethyl ester.

- In a 3-necked round bottomed flask fitted with a Dean-Stark apparatus 5-Fluoro-benzofuran-3-carbaldehyde (3.59 g, 21.9 mmol) and (4-amino-2-nitro-phenyl)-carbamic acid ethyl ester (4.48 g, 19.9 mmol) were mixed in o-xylene (80 mL) and a catalytic amount of acidic ion exchange resin (Amberlite IRC-84, 100 mg) was added.
- 5 The mixture was heated to reflux for 5 hours, filtered warm and concentrated *in vacuo*. This crude product was dissolved in a dioxane:methanol (4:1) mixture (90 mL) and sodiumborohydride (1.50 g, 39.8 mmol) was added portionwise over a period of 30 minutes. The reaction mixture was stirred at ambient temperature over night, then poured into water (200 mL) and extracted with ethyl acetate (3 x 75 mL). The
- 10 combined organic fractions were washed with brine, dried (MgSO_4) and evaporated to give a crude solid which was purified by chromatography on silica gel (eluent: ethyl acetate:heptane 1:2). This furnished 4.50 g (61%) of the title compound as a red crystalline material. ^1H NMR (CDCl_3): 1.33 (t, 3H); 4.07 (t, 1H); 4.23 (q, 2H); 4.42 (d, 2H); 6.99 (dd, 1H); 7.05 (dt, 1H); 7.25 (dd, 1H); 7.42 (t, 1H); 7.44 (d, 1H); 7.65 (s, 1H); 8.31 (d, 1H); 9.39 (s, 1H).
- 15

The following intermediates were prepared analogously:

- {4-[(5-Methyl-thiophen-2-ylmethyl)-amino]-2-nitro-phenyl}-carbamic acid ethyl ester
20 Yield: 73%. LC/MS (*m/z*) 336 (MH^+); t_R = 3.41 min.

- {4-[(3-Methyl-thiophen-2-ylmethyl)-amino]-2-nitro-phenyl}-carbamic acid ethyl ester
Yield: 89%. LC/MS (*m/z*)
{4-[(Thiophen-2-ylmethyl)-amino]-2-nitro-phenyl}-carbamic acid ethyl ester
25 Yield: 71%. LC/MS (*m/z*) 321 (MH^+); t_R = 3.24 min.

- {4-[(Thiophen-3-ylmethyl)-amino]-2-nitro-phenyl}-carbamic acid ethyl ester
Yield: 69%. LC/MS (*m/z*) 320 (MH^+); t_R = 3.08 min.

30 {4-(Benzo[*b*]thiophen-3-ylmethyl)-amino]-2-nitro-phenyl}-carbamic acid ethyl ester
Yield: 87%. M.p. 151-152 °C. LC-MS (*m/z*) 371.0 (MH^+), t_R = 3.59 min.
N-(4-Amino-2-nitrophenyl)-2-(4-fluorophenyl)acetamide.

To a stirred suspension of {4-[2-(4-fluorophenyl)-acetylamino]-3-nitro-phenyl}-carbamic acid *tert*-butyl ester (2.40 g, 6.16 mmol) in methylene chloride (5 mL) trifluoroacetic acid (5 mL) was added. After 15 minutes methylene chloride was distilled off and the residual solution was transferred into saturated aqueous NaHCO₃ solution (200 mL) with sonication. The precipitate was filtered, washed with water and dried *in vacuo* to furnish 1.70 g of the title compound as a red-brown solid. Yield 96.3%. LC/MS; t_R = 2.25 (UV, ELSD) 89%, 100%. ¹H NMR (DMSO-d₆): 3.59 (s, 2H); 5.65 (b, 2H, NH₂); 6.83 (dd, 1H); 7.08 (d, 1H); 7.15 (t, 2H), 7.21 (d, 1H); 7.32 (dd, 2H); 9.91 (s, 1H, NH).

10

The following compound was prepared analogously:

N-(4-Amino-2-nitrophenyl)-3,3-dimethylbutyramide.

Yield 680 mg, 93%. LC/MS (*m/z*) 293.43 ([M+H+MeCN]⁺); t_R = 2.29 (UV, ELSD) 99.5%, 99.1%. ¹H NMR (DMSO-d₆): 1.00 (s, 9H); 2.12 (s, 2H); 3.45 (b, H₂O+NH₂); 6.84 (dd, 1H); 7.06 (d, 1H); 7.14 (d, 1H); 9.64 (s, 1H, NH).

Preparation of intermediates of the general formula VIII

20 *N*-{4-[(5-Chlorothiophen-2-ylmethyl)amino]-2-nitrophenyl}-2-(4-fluorophenyl)acetamide.

A solution of *N*-(4-amino-2-nitrophenyl)-2-(4-fluorophenyl)acetamide (306 mg, 1.06 mmol) and 5-chloro-2-thiophenecarboxaldehyde (186 mg, 1.2 eq.) in anhydrous ethanol (40 mL) was heated at 70 °C for 30 minutes. The obtained solution was concentrated to a small volume (ca. 3 mL) and quenched with heptane (15 mL). The brown crystalline product was separated by filtration to furnish 350 mg of intermediate imine *N*-{4-[(5-chlorothiophen-2-ylmethylene)amino]-2-nitrophenyl}-2-(4-fluorophenyl)acetamide. Yield 79.2%. ¹H NMR (DMSO-d₆): 3.71 (s, 2H); 7.17 (t, 2H); 7.29 (d, 1H); 7.36 (dd, 2H); 7.62 (d, 1H); 7.63 (dd, 1H); 7.71 (d, 1H); 8.83 (s, 1H); 10.44 (s, 1H). The solid was suspended in methanol (5 mL), NaBH₃CN (200 mg) was added followed by acetic acid (2 mL). The obtained solution turned into a suspension. After 15 minutes it was treated with water (50 mL) and the product was separated by filtration to furnish 330 mg of red solid after drying *in vacuo*. Yield 93.8%. LC/MS (*m/z*) 420 ([M+H]⁺); t_R = 3.34 (UV, ELSD) 97%, 100%. ¹H NMR

(DMSO-d₆): 3.60 (s, 2H); 4.45 (d, 2H); 6.87 (t, 1H, NH); 6.93 (dd, 1H); 6.94 (d, 1H); 6.97 (d, 1H); 7.11 (d, 1H); 7.14 (t, 2H); 7.28 (d, 1H); 7.32 (dd, 2H); 9.98 (s, 1H).

The following compound was prepared analogously from the corresponding aniline:

5

N-{4-[*(5-Chlorothiophen-2-ylmethyl)amino*]-2-nitrophenyl}-3,3-dimethylbutyramide.

The crude intermediate imine was separated by evaporation and reduced as described above. Then, the reaction mixture was evaporated to a small volume, treated with saturated aqueous NaHCO₃ and ethyl acetate and the organic layer was evaporated.

10 The residue was dissolved in hot diisopropyl ether, precipitated with heptane and filtered. Yield 880 mg, 87.6%. LC/MS (*m/z*) 382.48 ([M+H]⁺); t_R = 3.46 (UV, ELSD) 88%, 91%. ¹H NMR (DMSO-d₆): 0.99 (s, 9H); 2.12 (s, 2H); 4.45 (d, 2H); 6.84 (t, 1H, NH); 6.92 (dd, 1H); 6.94 (d, 1H); 6.97 (d, 1H); 7.07 (d, 1H); 7.19 (d, 1H); 9.69 (s, 1H).

15

Preparation of intermediates of the general formula XII

{4-[2-(4-Fluorophenyl)acetylamino]-3-nitrophenyl}carbamic acid *tert*-butyl ester.

To a suspension of (4-amino-3-nitrophenyl)-carbamic acid *tert*-butyl ester (1.992 g, 20 7.87 mmol) and NaHCO₃ (5.4 g) in acetonitrile (20 mL) (4-fluorophenyl)acetyl chloride was added (1.8 mL, 1.3 eq.). The obtained suspension was sonicated for 5 minutes and stirred at ambient temperature for 16 hrs. It was poured into water (200 mL), sonicated for 5 minutes, filtered, and washed with water and heptane. The obtained residue was dissolved in hot ethyl acetate (30 mL), saturated aqueous 25 NaHCO₃ was added (50 mL) and the obtained mixture was quenched with heptane (200 mL). The obtained suspension was sonicated for 5 minutes and filtered. The residue was washed with water and heptane and dried *in vacuo* to furnish 2.48 g of a brown-yellow solid. Yield 80.9%. LC/MS (*m/z*) 412.54 ([M+Na]⁺), 453.58 ([M+MeCN+Na]⁺); t_R = 3.33 (UV, ELSD) 97%, 100%. ¹H NMR (DMSO-d₆): 1.48 (s, 30 9H); 3.66 (s, 2H); 7.16 (t, 2H), 7.34 (dd, 2H); 7.54 (d, 1H); 7.64 (dd, 1H); 8.16 (d, 1H); 9.79 (s, 1H, NH), 10.29 (s, 1H, NH).

The following compound was prepared analogously using the corresponding acid chloride:

[4-(3,3-Dimethylbutyrylamino)-3-nitrophenyl]carbamic acid tert-butyl ester.

The reaction mixture was stirred at 45 °C for 30 minutes with an excess of *tert*-butylacetyl chloride (3 eq.). The crude product was separated after ethyl acetate – saturated aqueous NaHCO₃ work-up and purified by flash chromatography on SiO₂ (50 g) with 10-15% ethyl acetate – heptane as an eluent. Yield 2.20 g (78.6%), yellow solid. LC/MS (*m/z*) 415.58 ([M+MeCN+Na]⁺); t_R = 3.31 (UV, ELSD) 99.5%, 99.9%. ¹H NMR (DMSO-d₆): 1.01 (s, 9H); 1.49 (s, 9H); 2.17 (s, 2H); 7.43 (d, 2H); 7.63 (dd, 1H); 8.11 (d, 1H); 9.77 (s, 1H, NH); 10.01 (s, 1H, NH).

.10

Compounds of the invention

Acid addition salts of the compounds of the invention may easily be formed by methods known to the person skilled in the art.

15

Example 1

1a {2-Amino-4-[(5-fluoro-benzofuran-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.

{4-[(5-Fluoro-benzofuran-3-ylmethyl)-amino]-2-nitro-phenyl}-carbamic acid ethyl ester (4.50 g, 12.1 mmol) was dissolved in absolute ethanol (140 mL) whereto 6N aqueous HCl (38 mL) and iron powder (5.70 g, 0.10 mol) was added. The red mixture was heated at 60 °C until the intense colour disappeared (20 minutes). The solids were filtered off and the ethanol was removed from the filtrate by evaporation *in vacuo*. Aqueous ammonia (saturated) was added to the remanence, which was then extracted with ethyl acetate (3 x 100 mL). The combined organic fractions were washed with brine, dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by chromatography on silica gel (eluent: ethyl acetate:heptane 1:1) to furnish 2.70 g (66%) of the title compound as a solid. M.p. 150-151 °C. Calculated for C₁₈H₁₈FN₃O₃: C 62.96; H 5.28; N 12.24. Found: C 63.00; H 5.38; N 12.13. LC/MS (*m/z*) 344 (MH⁺); t_R = 2.00 min. ¹H NMR (DMSO-d₆): 1.19 (t, 3H); 4.03 (q, 2H); 4.26 (d, 2H); 4.55 (s, 2H, NH₂); 5.79 (t, 1H); 5.91 (dd, 1H); 6.02 (d, 1H, NH); 6.72 (d, 1H); 7.13 (dt, 1H); 7.56 (m, 2H); 7.95 (s, 1H); 8.16 (b, 1H, NH).

The following compounds were prepared analogously and isolated as their hydrochloric acid addition salts:

5 **1b {2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester dihydrochloride.**

Precipitation of the crude product from ethyl acetate by addition of ethereal hydrochloric acid gave the title compound.

M.p. 190 °C (dec.). Calculated for C₁₅H₁₉N₃O₂S,2HCl: C 47.00; H 5.67; N 10.97.

Found: C 46.84; H 5.86; N 11.10. LC/MS (*m/z*) 306 (MH⁺); t_R = 1.77 min. ¹H NMR (DMSO-*d*₆): 1.22 (t, 3H); 2.37 (s, 3H); 4.08 (q, 2H); 4.37 (s, 2H); 6.64 (m, 1H); 6.67 (dd, 1H); 6.72 (d, 1H); 6.86 (d, 1H); 7.13 (d, 1H); 8.93 (b, 1H, NH).

10 **1c {2-Amino-4-[(3-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester dihydrochloride.**

Precipitation of the crude product from ethyl acetate by addition of ethereal hydrochloric acid gave the title compound.

15 LC/MS (*m/z*) 306 (MH⁺); t_R = 1.68 min. ¹H NMR (CDCl₃) (free base): 1.25 (t, 3H); 2.23 (s, 3H); 3.78 (b, 3H); 4.13 (q, 2H); 4.32 (s, 2H); 6.05-6.10 (m, 2H + NH); 6.82 (d, 1H); 6.93 (d, 1H); 7.11 (d, 1H).

20 **1d {2-Amino-4-[(thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester dihydrochloride.**

Precipitation of the crude product from ethanol by addition of ethereal hydrochloric acid gave the title compound.

M.p. 195 °C. Calculated for C₁₄H₁₇N₃O₂S,2HCl: C 46.16; H 5.26; N 11.54. Found: C

25 46.34; H 5.43; N 11.28. LC/MS (*m/z*) 292 (MH⁺); t_R = 1.58 min. ¹H NMR (DMSO-*d*₆): 1.22 (t, 3H); 4.08 (q, 2H); 4.48 (s, 2H); 6.71 (dd, 1H); 6.79 (d, 1H); 6.97 (dd, 1H); 7.10 (d, 1H); 7.16 (d, 1H); 7.40 (d, 1H); 8.97 (b, 1H, NH).

30 **1e {2-Amino-4-[(thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester dihydrochloride.**

Precipitation of the crude product from ethyl acetate by addition of ethereal hydrochloric acid gave the title compound.

M.p. 196-197 °C. Calculated for C₁₄H₁₇N₃O₂S, 2HCl: C 46.16; H 5.26; N 11.54.

Found: C 46.23; H 5.47; N 11.30. LC/MS (*m/z*) 292 (MH⁺); t_R = 1.54 min. ¹H NMR (DMSO-*d*₆): 1.21 (t, 3H); 4.08 (q, 2H); 4.29 (s, 2H); 6.66 (dd, 1H); 6.73 (d, 1H); 7.14 (dd, 1H); 7.16 (d, 1H); 7.45 (m, 1H); 7.51 (dd, 1H); 8.86 (b, 1H, NH).

5

1f {2-Amino-4-[{benzo[b]thiophen-3-ylmethyl}-amino]-phenyl}-carbamic acid ethyl ester dihydrochloride

Precipitation of the crude product from ethyl acetate by addition of ethereal hydrochloric acid gave the title compound.

- 10 M.p. 213-214 °C. Calculated for C₁₈H₂₁N₃Cl₂O₂S: C 51.68; H 4.95; N 10.05. Found: C 51.88; H 5.35; N 9.95. LC/MS (*m/z*) 342.2 (M+H⁺); t_R = 2.08 min. ¹H NMR (DMSO-*d*₆): 1.22 (t, 3H); 4.08 (q, 2H); 4.53 (s, 2H); 6.81 (dd, 1H); 6.93 (d, 1H); 7.19 (d, 1H); 7.41 (m, 2H); 7.70 (s, 1H); 7.98 (m, 2H); 8.97 (b, 1H, NH).

15 **Example 2**

2a (2-Amino-4-{[4-(4-chloro-benzenesulfonyl)-3-methyl-thiophen-2-ylmethyl]-amino}-phenyl)-carbamic acid ethyl ester.

A suspension of 4-(4-chloro-benzenesulfonyl)-3-methyl-thiophene-2-carbaldehyde (301 mg, 1.00 mmol) and (4-amino-2-nitro-phenyl)-carbamic acid ethyl ester (293

- 20 mg, 1.30 mmol) in absolute ethanol (10 mL) was heated under reflux for 20 h under N₂. After cooling, the orange to red solid imine formed was collected by filtration and vacuum dried to yield a crude product (312 mg, 61%), which was suspended in methanol:acetic acid 10:1 (10 mL). NaBH₃CN (0.19 g, 3.0 mmol) was added and the mixture was stirred for 1 hour at room temperature. Then another portion of

- 25 NaBH₃CN (0.19 g, 3.0 mmol) was added, and after further 1 hour, saturated aqueous sodium bicarbonate (20 mL) was added. The red solid amine formed was collected by filtration and vacuum dried to yield a crude product (293 mg, 94%) which was suspended in absolute ethanol (10 mL). To this was added 6 N HCl (1.1 mL, 6.6 mmol) and iron powder (193 mg, 3.46 mmol), and the red mixture was heated to 60

- 30 °C until the red color had faded to yellow, *ca.* 10-20 minutes. The mixture was poured into saturated aqueous sodium bicarbonate (50 mL) and EtOAc (50 mL), the resulting mixture was filtered, the phases were separated, and the aqueous phase was further extracted with EtOAc (2 × 50 mL). The combined organic phases were dried

(Na_2SO_4) and the solvents evaporated *in vacuo*. The product was purified by chromatography on silica gel on a FlashMaster system using as eluent heptane/ethyl acetate (linear gradient elution, typically from 8:2 to 1:1). The fractions containing the product were pooled and evaporated *in vacuo* to yield the title compound as a pale yellow solid (213 mg, 78%). LC-MS: (*m/z*) = 480.1 ($\text{M}+\text{H}^+$), calcd for $\text{C}_{21}\text{H}_{23}\text{ClN}_3\text{O}_4\text{S}_2$: 480.0813, $t_{\text{R}} = 2.35$ min, UV purity = 72.4%, ELS purity = 86.5%. ^1H NMR (DMSO-*d*₆): 1.19 (b, 3 H), 2.16 (s, 3 H), 4.02 (q, *J* = 6.9 Hz, 2 H), 4.23 (d, *J* = 6.1 Hz, 2 H), 4.57 (s, 2 H), 5.81 (dd, *J* = 2.4, 8.5 Hz, 1 H), 5.91-5.95 (m, 2 H), 6.72 (broad d, *J* = 6.6 Hz, 1 H), 7.72 (d, *J* = 8.5 Hz, 2 H), 7.90 (d, *J* = 8.5 Hz, 2 H), 8.15 (b, 1 H), 8.31 (s, 1 H).

The following compounds were prepared analogously:

2b {2-Amino-4-[{(3-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester}

Yield: 76%. LC-MS: (*m/z*) = 326.0 ($\text{M}+\text{H}^+$), calcd for $\text{C}_{14}\text{H}_{17}\text{ClN}_3\text{O}_2\text{S}$: 326.0725, $t_{\text{R}} = 1.95$ min, UV purity = 85.8%, ELS purity = 98.1%. ^1H NMR (DMSO-*d*₆): 1.19 (b, 3 H), 4.03 (q, *J* = 7.1 Hz, 2 H), 4.30 (d, *J* = 6.1 Hz, 2 H), 4.57 (s, 2 H), 5.83 (dd, *J* = 2.4, 8.5 Hz, 1 H), 5.93-5.97 (m, 2 H), 6.73 (broad d, *J* = 7.1 Hz, 1 H), 6.99 (d, *J* = 5.2 Hz, 1 H), 7.48 (d, *J* = 5.2 Hz, 1 H), 8.16 (b, 1 H).

20

2c {2-Amino-4-[{(4-bromo-3-methoxy-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.

Yield: 66%. LC-MS: (*m/z*) = 402.0 ($\text{M}+\text{H}^+$), calcd for $\text{C}_{15}\text{H}_{19}\text{BrN}_3\text{O}_3\text{S}$: 400.0325 (100%), 402.0310 (97.3%), $t_{\text{R}} = 1.97$ min, UV purity = 87.9%, ELS purity = 98.2%.

25 ^1H NMR (DMSO-*d*₆): 1.20 (b, 3 H), 3.83 (s, 3 H), 4.03 (q, *J* = 6.9 Hz, 2 H), 4.32 (d, *J* = 6.1 Hz, 2 H), 4.58 (s, 2 H), 5.84-5.89 (m, 2 H), 5.97 (d, *J* = 2.4 Hz, 1 H), 6.74 (b, 1 H), 7.46 (s, 1 H), 8.17 (b, 1 H).

30 **2d {2-Amino-4-[{(6-chloro-3-methoxy-benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.**

Yield: 60%. LC-MS: (*m/z*) = 405.3 ($\text{M}+\text{H}^+$), calcd for $\text{C}_{19}\text{H}_{21}\text{ClN}_3\text{O}_3\text{S}$: 406.0987, $t_{\text{R}} = 2.39$ min, UV purity = 95.0%, ELS purity = 99.6%. ^1H NMR (DMSO-*d*₆): 1.19 (b, 3 H), 3.95 (s, 3 H), 4.02 (q, *J* = 7.1 Hz, 2 H), 4.43 (d, *J* = 6.1 Hz, 2 H), 4.56 (s, 2 H), 5.90 (dd, *J* = 2.4, 8.5 Hz, 1 H), 5.96 (t, *J* = 5.9 Hz, 1 H), 6.00 (d, *J* = 2.8 Hz, 1 H),

6.73 (broad d, $J = 6.6$ Hz, 1 H), 7.39 (dd, $J = 1.9, 8.5$ Hz, 1 H), 7.68 (d, $J = 8.5$ Hz, 1 H), 7.98 (d, $J = 1.9$ Hz, 1 H), 8.15 (b, 1 H).

2e {2-Amino-4-[(5-dimethyl-amino-benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.

Yield: 13%. LC-MS: (m/z) = 385.0 ($M+H^+$), calcd for $C_{20}H_{25}N_4O_2S$: 385.1693, $t_R = 1.29$ min, UV purity = 87.8%, ELS purity = 93.5%. 1H NMR (DMSO- d_6): 1.19 (b, 3 H), 2.94 (s, 6 H), 4.02 (q, $J = 6.9$ Hz, 2 H), 4.34 (d, $J = 5.7$ Hz, 2 H), 4.53 (s, 2 H), 5.81 (t, $J = 5.9$ Hz, 1 H), 5.93 (dd, $J = 2.4, 8.5$ Hz, 1 H), 6.03 (d, $J = 2.4$ Hz, 1 H), 6.72 (b, 1 H), 6.95 (dd, $J = 2.4, 9.0$ Hz, 1 H), 7.08 (d, $J = 2.4$ Hz, 1 H), 7.38 (s, 1 H), 7.71 (d, $J = 8.5$ Hz, 1 H), 8.15 (b, 1 H).

2f {2-Amino-4-[(5-dimethyl-amino-3-methyl-benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.

Yield: 36%. LC-MS: (m/z) = 399.2 ($M+H^+$), calcd for $C_{21}H_{27}N_4O_2S$: 399.1849, $t_R = 1.31$ min, UV purity = 98.4%, ELS purity = 99.4%. 1H NMR (DMSO- d_6): 1.19 (b, 3 H), 2.33 (s, 3 H), 2.93 (s, 6 H), 4.02 (q, $J = 6.9$ Hz, 2 H), 4.37 (d, $J = 5.7$ Hz, 2 H), 4.54 (s, 2 H), 5.86 (dd, $J = 2.4, 8.5$ Hz, 1 H), 5.89 (t, $J = 6.6$ Hz, 1 H), 5.96 (d, $J = 2.4$ Hz, 1 H), 6.71 (b, 1 H), 6.84-6.89 (m, 2 H), 7.58 (d, $J = 8.5$ Hz, 1 H), 8.16 (b, 1 H).

20

Example 3

3a {2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-(methyl)-amino]-phenyl}-carbamic acid ethyl ester.

A mixture of 5-methyl-2-thiophenecarboxaldehyde (108 μ L, 1.00 mmol), (4-amino-2-nitro-phenyl)-carbamic acid ethyl ester (225 mg, 1.00 mmol) and Amberlite IRC-84 (10 mg) in *o*-xylene (4 mL) was heated at reflux under Ar for 5 hours. Volatiles were removed by evaporation *in vacuo*, and the residue was dissolved in acetonitrile (5 mL). To the resulting solution was added NaBH₃CN (0.25 g, 4.0 mmol) followed by HOAc (5 drops). After stirring for 5 minutes, the solution became dark red.

Formaldehyde (37% solution in water, 0.89 mL, 12 mmol) was added, and stirring was continued for 30 minutes with occasional addition of HOAc. The reaction mixture was evaporated to dryness *in vacuo* and the residue was partitioned between saturated aqueous sodium bicarbonate (50 mL) and EtOAc (50 mL). The aqueous phase was extracted with EtOAc (50 mL) and the combined organic layers were dried

(Na_2SO_4) and the solvents evaporated *in vacuo*. The residue was then dissolved in ethanol (10 mL). 6 N aqueous HCl (2.0 mL, 12 mmol) and iron powder (0.34 g, 6.0 mmol) were added, and the red mixture was heated at 60 °C until the red color had faded to yellow, *ca.* 15 minutes. The mixture was poured into saturated aqueous sodium bicarbonate (50 mL) and EtOAc (50 mL), the resulting mixture was filtered, the phases were separated, and the aqueous phase was further extracted with EtOAc (2 × 50 mL). The combined organic layers were dried (Na_2SO_4) and the solvents evaporated *in vacuo*. The product was purified by chromatography on silica gel on a FlashMaster system using as eluent heptane/ethyl acetate (linear gradient elution, typically from 8:2 to 1:1). The fractions containing the product were pooled and evaporated *in vacuo* to yield the title compound as a pale yellow solid (145 mg, 45% overall). LC-MS: (*m/z*) = 319.9 ($\text{M}+\text{H}^+$), calcd for $\text{C}_{16}\text{H}_{22}\text{N}_3\text{O}_2\text{S}$: 320.1427, $t_{\text{R}} = 1.80$ min, UV purity = 98.4%, ELS purity = 97.2%. ^1H NMR (CDCl_3): 1.29 (t, $J = 7.1$, 3 H), 2.41 (s, 3 H), 2.91 (s, 3 H), 3.76 (b, 2 H), 4.19 (q, $J = 7.1$ Hz, 2 H), 4.52 (s, 2 H), 6.02 (b, 1 H), 6.17 (d, $J = 2.8$ Hz, 1 H), 6.25 (dd, $J = 2.8$, 8.5 Hz, 1 H), 6.53-6.58 (m, 1 H), 6.66 (d, $J = 3.3$ Hz, 1 H), 6.98 (d, $J = 8.5$ Hz, 1 H).

The following compound was prepared analogously:

20 **3b** {2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-(methyl)-amino]-phenyl}-carbamic acid ethyl ester.
Yield: 34%. LC-MS: (*m/z*) = 340.0 ($\text{M}+\text{H}^+$), calcd for $\text{C}_{15}\text{H}_{19}\text{ClN}_3\text{O}_2\text{S}$: 340.0881, $t_{\text{R}} = 2.14$ min, UV purity = 82.3%, ELS purity = 90.2%. ^1H NMR (CDCl_3): 1.29 (t, $J = 6.8$, 3 H), 2.91 (s, 3 H), 3.78 (b, 2 H), 4.20 (q, $J = 7.2$ Hz, 2 H), 4.49 (s, 2 H), 6.05 (b, 1 H), 6.16 (d, $J = 2.4$ Hz, 1 H), 6.24 (dd, $J = 2.4$, 8.5 Hz, 1 H), 6.73 (d, $J = 3.8$ Hz, 1 H), 6.99 (d, $J = 8.5$ Hz, 1 H).

The following compound was prepared analogously, except that formaldehyde was substituted for acetaldehyde:

30 **3c** {2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-(ethyl)-amino]-phenyl}-carbamic acid ethyl ester.

Yield: 12%. LC-MS: (*m/z*) = 353.9 (M+H⁺), calcd for C₁₆H₂₁ClN₃O₂S: 354.1038, t_R = 2.02 min, UV purity = 97.5%, ELS purity = 99.0%. ¹H NMR (CDCl₃): 1.16 (t, *J* = 7.1, 3 H), 1.29 (t, *J* = 6.8, 3 H), 3.36 (q, *J* = 7.1 Hz, 2 H), 3.76 (b, 2 H), 4.19 (q, *J* = 7.2 Hz, 2 H), 4.47 (s, 2 H), 6.05 (b, 1 H), 6.13 (d, *J* = 2.4 Hz, 1 H), 6.19 (dd, *J* = 2.4, 5 9.0 Hz, 1 H), 6.73 (d, *J* = 3.8 Hz, 1 H), 6.96 (d, *J* = 8.0 Hz, 1 H).

The following compound was prepared analogously, except that the formaldehyde addition was omitted:

10 *3d {2-Amino-4-[(5-fluoro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester*

Yield: 65% (25% after prep. LC-MS purification to remove non-fluorinated by-product). LC-MS: (*m/z*) = 310.2 (M+H⁺), calcd for C₁₄H₁₇FN₃O₂S: 310.1020, t_R = 1.76 min, UV purity = 96.6%, ELS purity = 83.4%. ¹H NMR (CDCl₃): 1.29 (b, 3 H), 15 3.82 (b, 2 H), 4.19 (q, *J* = 7.2 Hz, 2 H), 4.31 (d, *J* = 2.0 Hz, 2 H), 6.05 (b, 1 H), 6.09 (d, *J* = 8.0 Hz, 1 H), 6.29 (dd, *J* = 1.5, 3.8 Hz, 1 H), 6.58 (t, *J* = 3.5 Hz, 1 H), 6.94 (d, *J* = 8.0 Hz, 1 H).

Example 4

20 *4a {2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.*

A solution of 5-chlorothiophene-2-carbaldehyde (240 μ L, 111 μ mol, 463 mM in 1,2-dichloroethane) was added to a solution of 4-amino-2-nitrophenylcarbamic acid ethyl ester (240 μ L, 111 μ mol, 463 mM in 1,2-dichloroethane). Sodium 25 triacetoxyborohydride (118 mg, 555 μ mol) was added, and the resulting mixture was stirred for 3.5 hours at 40 °C. The mixture was allowed to cool to ambient temperature, and water (100 μ L) was added. The mixture was filtered through silica gel (500 mg) and the column was washed with 1,2-dichloroethane (3 mL). The combined organic phases were evaporated to dryness *in vacuo*. The resulting solid 30 was dissolved in ethanol (3 mL). Iron (19 mg) was added to one-third of the resulting solution (1 mL), followed by an aqueous solution of hydrochloric acid (96 μ L, 6M). The resulting mixture was placed in an ultrasonic bath for 10 minutes. Then, saturated aqueous sodium bicarbonate solution (2 mL) was added. The mixture was extracted

with ethyl acetate (3 mL). The organic phase was washed with water (3 mL) and brine (3 mL), dried over magnesium sulphate, filtered, and evaporated to dryness *in vacuo*. The resulting product was dissolved in 190 μ L dimethylsulfoxide and subjected to preparative LC-MS purification. The resulting solution was evaporated to dryness *in vacuo*. Yield (6.8 mg, 56%). LC-MS (*m/z*) ($M+H$)⁺ 326.1 RT=1.90 (UV, ELSD) 92%, 99%.

The following compounds were prepared in an analogous fashion:

10 **4b** {2-Amino-4-[(5-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.

LC-MS (*m/z*) ($M+H$)⁺ 371.9 RT=1.94 (UV, ELSD) 89%, 98%.

15 **4c** {2-Amino-4-[(4-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.

LC-MS (*m/z*) ($M+H$)⁺ 372.0 RT=1.96 (UV, ELSD) 76%, 100%.

20 **4d** {2-Amino-4-[(5-ethyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.

LC-MS (*m/z*) ($M+H$)⁺ 320.1 RT=1.90 (UV, ELSD) 72%, 96%.

25 **4e** {2-Amino-4-[(benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.

LC-MS (*m/z*) ($M+H$)⁺ 342.1 RT=2.06 (UV, ELSD) 75%, 100%.

30 **4f** {2-Amino-4-[(5-phenyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester.

LC-MS (*m/z*) ($M+H$)⁺ 368.2 RT=2.21 (UV, ELSD) 90%, 99%.

Example 5

5a {2-Amino-4-[{benzo[b]thiophen-2-ylmethyl}-amino]-phenyl}-carbamic acid propyl ester

Benzo[b]thiophene-2-carbaldehyde (1.36 g, 8.38 mmol) was added to a solution of (4-

5 amino-2-nitro-phenyl)-carbamic acid propyl ester (2.00 g, 8.36 mmol) in acetonitrile (10 mL). The mixture was heated to 160 °C for 2 minutes in a 20 mL sealed microwave process vial. Upon cooling NaBH₃CN (1.06 g, 16.7 mmol) and AcOH (48 µL, 0.84 mmol) were added and the mixture was stirred for 30 minutes at 25 °C.

Water/brine (1:1, 100 mL) was added and the mixture was extracted with ethyl acetate

10 (3x 100 mL). The organic phase was dried over magnesium sulphate, filtered and concentrated *in vacuo*. The crude intermediate was purified by flash chromatography on silica gel (eluent: ethyl acetate:heptane 1:9), and evaporated to dryness. The intermediate was then dissolved in tetrahydrofuran (20 mL) and Na₂S₂O₄ (3.67 g, 21 mmol) dissolved in water (50 mL) was added. The resulting mixture was stirred at

15 40°C for 5 hours under argon. The resulting mixture was extracted with ethyl acetate (3x 100 mL), the combined organic phases dried over magnesium sulphate, filtered, and concentrated *in vacuo*. Purification by flash chromatography (eluent: ethyl acetate:heptane 1:1) furnished 0.3 g (10%) of the title compound as a solid. LC/MS

(*m/z*) 356 ([M+H]⁺); RT = 2.45 min. ¹H NMR (CDCl₃): 0.95 (t, 3H); 1.67 (m, 2H);

20 4.08 (t, 2H); 4.55 (s, 2H); 6.08 (d, 1H); 6.13 (dd, 1H); 6.93 (d, 1H); 7.20 (s, 1H); 7.27 (dt, 1H); 7.32 (dt, 1H); 7.68 (d, 1H); 7.77 (d, 1H).

The following compound was prepared in an analogous fashion:

25 *5b {2-Amino-4-[{benzo[b]thiophen-3-ylmethyl}-amino]-phenyl}-carbamic acid propyl ester.*

Yield: 16%. LC/MS (*m/z*) 356 ([M+H]⁺); RT = 2.24 min. ¹H NMR (CDCl₃): 0.96 (t, 3H); 1.68 (m, 2H); 4.10 (t, 2H); 4.51 (s, 2H); 6.12 (d, 1H); 6.14 (dd, 1H); 6.95 (d, 1H); 7.36 (s, 1H); 7.39 (dt, 1H); 7.40 (dt, 1H); 7.79 (dd, 1H); 7.87 (dd, 1H).

30

Example 6

6a N-{2-Amino-4-[{(5-chlorothiophen-2-ylmethyl)amino}phenyl]-2-(4-fluorophenyl)-acetamide.

To a stirred red solution of N-{4-[(5-chlorothiophen-2-ylmethyl)amino]-2-nitrophenyl}-2-(4-fluorophenyl)acetamide (320 mg, 0.762 mmol) in tetrahydrofuran (25 mL) and acetic acid (8 mL) zinc powder (particle size <10 micron, 10 g) was periodically added by portions during 30 minutes. The solution turned colorless after 5 minutes. The obtained colorless suspension was filtered via plug of SiO₂ (10 g) with ethyl acetate as an eluent and the obtained solution was evaporated *in vacuo*. The obtained solid was dissolved in a mixture of ethyl acetate/acetone/trifluoroacetic (3 mL/3 mL/0.2 mL), treated with saturated aq. NaHCO₃ (50 mL) and heptane (30 mL) and the product was separated by filtration to furnish 280 mg of a pale grey solid.

10 Yield 94.2%. LC/MS (m/z) 390.4 ([M+H]⁺); RT = 2.26 (UV, ELSD) 99%, 100%. ¹H NMR (DMSO-d₆): 3.56 (s, 2H); 4.28 (d, 2H); 4.57 (s, 2H, NH₂); 5.87 (dd, 1H); 5.98 (m, 2H, NH and arom. H); 6.74 (d, 1H); 6.86 (d, 1H); 6.93 (d, 1H); 7.13 (t, 2H); 7.35 (dd, 2H); 9.10 (s, 1H).

15 The following compound was prepared analogously from the corresponding nitro compound:

6b N-{2-Amino-4-[(5-chlorothiophen-2-ylmethyl)amino]phenyl}-3,3-dimethylbutyramide.

20 After filtration through SiO₂ and evaporation the product was precipitated from a biphasic solution in ethyl acetate - saturated aq. NaHCO₃ (5 mL/20 mL) with heptane (50 mL). Yield 580 mg, 71.5%. LC/MS (m/z) 352.48 ([M+H]⁺); RT = 2.16 (UV, ELSD) 96%, 99%. ¹H NMR (DMSO-d₆): 1.01 (s, 9H), 2.11 (s, 2H); 4.29 (d, 2H); 4.54 (s, 2H, NH₂); 5.88 (dd, 1H); 5.97 (t, 1H, NH); 5.99 (d, 1H); 6.72 (d, 1H); 6.87 (d, 1H); 6.93 (d, 1H); 8.82 (s, 1H).

In vitro and in vivo testing

30 The compounds of the invention have been tested and shown effect in one or more of the below models:

Relative efflux through the KCNQ2 channel.

Cells stably expressing voltage-gated KCNQ2 channels were seeded on the day before the experiment and loaded with [⁸⁶Rb]. On the day of the experiment cells were

washed with a HBSS-containing buffer. Cells were preincubated with drug and the [⁸⁶Rb+] was stimulated by a submaximal concentration of 15 mM KCl in the continued presence of drug. After a suitable incubation period, the supernatant was removed and counted in a liquid scintillation counter (Tricarb). Cells were lysed with 5 2 mM NaOH and the amount of ⁸⁶Rb+ was counted. The relative efflux was calculated ((CPM_{suoer}/CPM_{super}+ CPM_{cell})_{Cmpd}/ (CPM_{suoer}/CPM_{super}+ CPM_{cell})_{15mM kcl})*100-100.

10 The compounds of the invention have an EC₅₀ of less than 2000nM, in most cases less than 2000nM and in many cases less than 200nM. Accordingly, the compounds of the invention are considered to be useful in the treatment of diseases associated with the KCNQ family potassium channels.

Maximum electroshock

15 The test was conducted in groups of male mice using corneal electrodes and administering a square wave current of 26 mA for 0.4 seconds in order to induce a convulsion characterised by a tonic hind limb extension (Wlaz et al. *Epilepsy Research* 1998, 30, 219-229).

20 **Pilocarpine induced seizures**

Pilocarpine induced seizures are induced by intraperitoneal injection of pilocarpine 250 mg/kg to groups of male mice and observing for seizure activity resulting in loss of posture within a period of 30 minutes (Starr et al. *Pharmacology Biochemistry and Behavior* 1993, 45, 321-325)

25

Electrical seizure -threshold test

A modification of the up-and-down method (Kimball et a., *Radiation Research* 1957, 30 1-12) was used to determine the median threshold to induce tonic hind-limb extension in response to corneal electroshock in groups of male mice. The first mouse of each group received an electroshock at 14 mA, (0.4 s, 50 Hz) and was observed for seizure activity. If a seizure was observed the current was reduced by 1mA for the next

mouse, however, if no seizure was observed then the current was increased by 1mA. This procedure was repeated for all 15 mice in the treatment group.

Chemical seizure -threshold test

5 The threshold dose of pentylenetetrazole required to induce a clonic convulsion was measured by timed infusion of pentylenetetrazole (5mg/mL at 0.5 mL/min) into a lateral tail vein of groups of male mice (Nutt et al. *J Pharmacy and Pharmacology* 1986, 38, 697-698).

10 **Amygdala kindling**

Rats underwent surgery to implantation of tri-polar electrodes into the dorsolateral amygdala. After surgery the animals were allowed to recover before the groups of rats received either varying doses of test compound or the drug's vehicle. The animals were stimulated with their initial after discharge threshold + 25 µA daily for 3-5 weeks and on each occasion seizure severity, seizure duration, and duration of electrical after discharge were noted. (Racine. *Electroencephalography and Clinical Neurophysiology* 1972, 32, 281-294)


20 **Side effects**

Central nervous system side-effects were measured by measuring the time mice would remain on rotarod apparatus (Capacio et al. *Drug and Chemical Toxicology* 1992, 15, 177-201); or by measuring their locomotor activity by counting the number of infra-red beams crossed in a test cage ((Watson et al. *Neuropharmacology* 1997, 36, 1369-1375). Hypothermic actions on the animals core body temperature of the compound were measured by either rectal probe or implanted radiotelemetry transmitters capable of measuring temperature (Keeney et al. *Physiology and Behaviour* 2001, 74, 177-184).

30

Pharmacokinetics

The pharmacokinetic properties of the compound were determined via. i.v. and p.o. dosing to Sprague Dawley rats, and, thereafter, drawing blood samples over 20 hours. Plasma concentrations were determined with LC/MS/MS.

Claims**1. A 1,2,4-triaminobenzene derivative of formula I**

5

wherein

R¹ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl;

R² and **R^{2'}** are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, aryl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl-C₁₋₆-alk(en/yn)yl, acyl, hydroxy-C₁₋₆-alk(en/yn)yl and hydroxy-C₃₋₈-cycloalk(en)yl;

R³ is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, aryl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, aryl-C₃₋₈-cycloalk(en)yl, NR¹⁰R^{10'}-C₁₋₆-alk(en/yn)yl,

NR¹⁰R^{10'}-C₃₋₈-cycloalk(en)yl and hydroxy-C₃₋₈-cycloalk(en)yl; wherein

R¹⁰ and **R^{10'}** are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, hydroxy-C₃₋₈-cycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl, hydroxy-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₃₋₈-cycloalk(en)yl,

halo-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, cyano-C₃₋₈-cycloalk(en)yl and cyano-C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, or

25

R^{10} and $R^{10'}$ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms;

5 X is CO or SO_2 ;

Z is O or NR^4 , wherein


R^4 is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, hydroxy- C_{1-6} -alk(en/yn)yl and hydroxy- C_{3-8} -cycloalk(en)yl; or

10 R^3 and R^4 together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms, the ring formed by R^3 and R^4 and the nitrogen atom is optionally substituted with one or more substituents independently selected from C_{1-6} -alk(en/yn)yl, aryl and aryl- C_{1-6} -alk(en/yn)yl;


15 q is 0 or 1;

and

20 Y represents a heteroaryl of formula II or III



II



III

25 wherein

W is O or S;

m is 0,1, 2 or 3;

n is 0, 1, 2, 3 or 4;

5

p is 0 or 1; and

each **R**⁵ is independently selected from the group consisting of C₁₋₆-alk(en/yn)yl,
C₃₋₈-cycloalk(en)yl, aryl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl-C₁₋₆-
10 alk(en/yn)yl, acyl, halogen, halo-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, -CO-
NR⁶R^{6'}, cyano, nitro, -NR⁷R^{7'}, -S-R⁸, -SO₂R⁸, SO₂OR⁸;

wherein

15 **R**⁶ and **R**^{6'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl and aryl;

20 **R**⁷ and **R**^{7'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl and
acyl; and


R⁸ is selected from the group consisting of C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl,
C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, aryl and -NR⁹R^{9'}; wherein

25 **R**⁹ and **R**^{9'} are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl;


or pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 wherein **R**¹ is selected from the group
30 consisting of hydrogen and C₁₋₆-alk(en/yn)yl.
3. A compound according to any one of claims 1 and 2 wherein at least one of the
substituents **R**² and **R**^{2'} is a hydrogen atom

4. A compound according to any one of claims 1-3 wherein both \mathbf{R}^2 and $\mathbf{R}^{2'}$ are hydrogen atoms.
5. A compound according to any one of claims 1-4 wherein \mathbf{X} is CO.
6. A compound according to any one of claims 1-5 wherein \mathbf{q} is 0.
7. A compound according to any one of claims 1-5 wherein \mathbf{q} is 1 and \mathbf{Z} is an oxygen atom.
10. 8. A compound according to any one of claims 1-7 wherein \mathbf{R}^3 is selected from the group consisting of $\text{C}_{1-6}\text{-alk(en/yn)yl}$ and $\text{aryl-C}_{1-6}\text{-alk(en/yn)yl}$.
9. A compound according to claim 8 wherein \mathbf{R}^3 is $\text{C}_{1-6}\text{-alk(en/yn)yl}$.
15. 10. A compound according to claim 8 wherein \mathbf{R}^3 is $\text{aryl-C}_{1-6}\text{-alk(en/yn)yl}$.
11. A compound according to any one of claims 1-10 wherein \mathbf{W} is an oxygen atom.
20. 12. A compound according to any one of claims 1-11 wherein \mathbf{W} is a sulfur atom.
13. A compound according to any one of claims 1-12 wherein \mathbf{Y} is of formula II.
14. A compound according to any one of claims 1-12 wherein \mathbf{Y} is of formula III.
25. 15. A compound according to any of claims 1-14 wherein \mathbf{Y} is of formula IIb or IIIb




IIb




IIIb

wherein \mathbf{W} , \mathbf{m} , \mathbf{n} , \mathbf{p} and \mathbf{R}^5 are as defined above.

16. A compound according to any of claims 1-14 wherein Y is of formula IIc or IIIc



IIc



IIIc

wherein W, m, n, p and R⁵ are as defined above.

- 5 17. A compound according to any one of claims 1-16 wherein each R⁵ is independently selected from the group consisting of C₁₋₆-alk(en/yn)yl, aryl, halogen, C₁₋₆-alk(en/yn)yloxy, -NR⁷R⁷, -SO₂R⁸.

- 10 18. A compound according to any of claims 1-17, said compound being selected from the group consisting of:

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-methyl-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(6-chloro-3-methoxy-benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(4-bromo-3-methoxy-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(5-phenyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(3-chloro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;

- (2-Amino-4-{{[4-(4-chloro-benzenesulfonyl)-3-methyl-thiophen-2-ylmethyl]-amino}-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(3-methyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- 5 {2-Amino-4-[(5-fluoro-benzofuran-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(4-bromo-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- 10 {2-Amino-4-[(5-ethyl-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-ethyl-amino]-phenyl}-carbamic acid ethyl ester;
- 15 {2-Amino-4-[(benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(5-dimethyl-amino-benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(5-dimethyl-lamino-3-methyl-benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- 20 {2-Amino-4-[(5-fluoro-thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid ethyl ester;
- {2-Amino-4-[(benzo[b]thiophen-2-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester;
- 25 {2-Amino-4-[(benzo[b]thiophen-3-ylmethyl)-amino]-phenyl}-carbamic acid propyl ester;
- N-{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)amino]phenyl}-2-(4-fluorophenyl)-acetamide; and
- N-{2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)amino]phenyl}-3,3-dimethylbutyramide
- 30 or a pharmaceutically acceptable salt thereof;

19. A pharmaceutical composition comprising a compound according to any of the claims 1-18 in a therapeutically effective amount together with one or more pharmaceutically acceptable carriers or diluents.
- 5 20. Use of a compound of any of claims 1-19 for the manufacture of a pharmaceutical preparation for the prevention, treatment and/or inhibition of a disorder of the central nervous system.
- 10 21. Use according to claim 20 characterized in that the disorder of the central nervous system is selected from the group consisting of seizure disorders such as convulsions, epilepsy and status epilepticus.
- 15 22. Use according to claim 21 characterized in that the disorder of the central nervous system is selected from the group consisting of neuropathic and migraine pain disorders such as allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine.
- 20 23. Use according to claim 21 characterized in that the disorder of the central nervous system is selected from the group consisting of anxiety disorders such as anxiety, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia, specific phobias, anxiety disorder due to general medical condition and substance-induced anxiety disorder.
- 25 24. Use according to claim 21 characterized in that the disorder of the central nervous system is selected from the group consisting of and neurodegenerative disorders such as Alzheimer's disease, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced encephalopathy and other infection-related encephalopathies being caused by rubella viruses, herpes viruses, borrelia and by unknown pathogens, Creutzfeld-Jakob disease, Parkinson's disease, trauma-induced neurodegenerations.

25. Use according to claim 21 characterized in that the disorder of the central nervous system is selected from the group consisting of neuronal hyperexcitation states such as in medicament withdrawal or by intoxication.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DR 2003/000906

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 333/20, C07D 333/28, C07D 333/32, C07D 333/64, C07D 307/82,
A61K 31/381, A61K 31/343, A61P 25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM. ABS DATA, EPO-INTERNAL, WPI DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 0101970 A2 (GLAXO GROUP LIMITED), 11 January 2001 (11.01.2001) --	1-25
X	WO 0122953 A2 (ASTA MEDICA AG), 5 April 2001 (05.04.2001) --	1-25
X	WO 9715300 A2 (ASTA MEDICA AKTIENGESELLSCHAFT), 1 May 1997 (01.05.1997) --	1-25
X	WO 0249628 A2 (WYETH), 27 June 2002 (27.06.2002) -----	1-25

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family

Date of the actual completion of the international search
24 March 2004Date of mailing of the international search report
26-03-2004Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86Authorized officer
Anna Sjölund/EÖ
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/DR/2003/000906

WO	0101970	A2	11/01/2001	AU	5557700	A	22/01/2001
				EP	1207863	A	29/05/2002
				GB	9915414	D	00/00/0000
				JP	2003503447	T	28/01/2003

WO	0122953	A2	05/04/2001	AU	7906100	A	30/04/2001
				BG	6450	A	30/09/2002
				BG	106450	A	30/09/2002
				BR	0014293	A	21/05/2002
				CA	2384504	A	05/04/2001
				CN	1409632	T	09/04/2003
				CZ	20020989	A	14/08/2002
				EE	200200145	A	15/04/2003
				EP	1223927	A	24/07/2002
				HR	20020234	A	30/06/2003
				HU	0202853	A	28/12/2002
				IL	148309	D	00/00/0000
				JP	2003510273	T	18/03/2003
				NO	20021418	A	21/03/2002
				NZ	517616	A	20/12/2002
				PL	353393	A	17/11/2003
				SK	2922002	A	06/08/2002
				TR	200200706	T	00/00/0000
				US	6117900	A	12/09/2000
				ZA	200202449	A	28/01/2003

WO	9715300	A2	01/05/1997	AT	178487	T	15/04/1999
				AU	706735	B	24/06/1999
				AU	1540097	A	15/05/1997
				BR	9610899	A	13/07/1999
				CA	2188841	A	27/04/1997
				CZ	291456	B	12/03/2003
				CZ	9801225	A	16/09/1998
				DE	19539861	A	30/04/1997
				DE	59601624	D	00/00/0000
				EP	0857065	A,B	12/08/1998
				SE	0857065	T3	
				ES	2131973	T	01/08/1999
				GR	3030336	T	30/09/1999
				HU	9900508	A	28/06/1999
				ID	16489	A	00/00/0000
				IL	123523	A	23/12/2001
				JP	11515007	T	21/12/1999
				NO	981503	A	02/04/1998
				NZ	326754	A	27/03/2000
				PL	185714	B	31/07/2003
				PL	325956	A	17/08/1998
				RU	2201227	C	27/03/2003
				SK	52098	A	09/09/1998
				SK	283222	B	04/03/2003
				TW	457084	B	00/00/0000
				US	5849789	A	15/12/1998
				US	5852053	A	22/12/1998
				ZA	9608991	A	10/06/1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/DR/2003/000906

WO	0249628	A2	27/06/2002	AU	3112202 A	01/07/2002
				CA	2431278 A	27/06/2002
				EP	1343495 A	17/09/2003
				US	6589986 B	08/07/2003
				US	2002111379 A	15/08/2002

INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 421 WO	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/DK 03/00906	International filing date (day/month/year) 18.12.2003	Priority date (day/month/year) 27.12.2002
International Patent Classification (IPC) or both national classification and IPC C07D333/20		
Applicant H.LUNDBECK A/S et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I Basis of the opinion
- II Priority
- III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 07.06.2004	Date of completion of this report 27.04.2005
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized Officer Boletti-Cremers, K Telephone No. +49 89 2399-8541



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/DK 03/00906

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-72 as originally filed

Claims, Numbers

1-25 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- the description, pages:
- the claims, Nos.:
- the drawings, sheets:

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/DK 03/00906

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-25
	No:	Claims	
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-25
Industrial applicability (IA)	Yes:	Claims	1-25
	No:	Claims	

2. Citations and explanations

see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/DK 03/00906

POINT V.

The following documents , quoted in the I.S.R., have been considered as relevant for the examination of the present application . Their numbering will be adhered to for the rest of the procedure.

- (1) WO-A-01 01970.
- (2) WO-A-01 22953 , quoted in the application.
- (3) WO 97 15300 , quoted in the application.
- (4) WO 02 49628 , quoted in the application.

1. Novelty.

None of the documents quoted above discloses the pharmacological compounds (I) of present application, which can therefore be considered as novel with respect to the prior art.

2. Inventiveness.

In view of the fact that the compounds of present application merely differ from the retigabine or retigabine derivatives disclosed in (1)-(4) by the replacement of the terminal phenyl radical by a condensed heterocycle (see the definitions of Y in this respect), they are considered to be likely to possess the same pharmacological profile as the retigabine disclosed in (1). Therefore present claims cannot yet be regarded as inventive and the Applicant will be invited, at the entry of the regional European proceedings, to show either by argumentation or technical evidence , that the claimed compounds on file possess any advantage or surprising feature when they are compared with retigabine in order to enable the acknowledgment of the inventiveness of the application with respect to the content of the prior art quoted above.

3. Formal points.

3.1 When the application will reach the regional proceedings, (1) should be mentioned and briefly discussed in the description .

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/DK 03/00906